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III Zusammenfassung 
 
Für die menschliche Gesundheit sowie auch für Krankheiten spielt das 
Darmmikrobiom eine wichtige Rolle. Fäkalien spiegeln dabei die mikrobielle Aktivität 
wider. Die Analyse der fäkalen Metaboliten liefert daher Einblicke in die metabolischen 
Wechselwirkungen zwischen Darmmikrobiota und Wirtsorganismus.  
 
In dieser Arbeit wird die Entwicklung einer Fließ-Injektion-Analyse beschrieben, welche 
mit einer Fourier-Transform-Massenspektrometrie-Messung (FIA-FTMS) gekoppelt 
ist, um Lipidspezies in menschlichen Fäkalien mit einem hohen Probendurchsatz zu 
identifizieren und quantifizieren. Fäkale Homogenate wurden gemäß dem Protokoll 
von Bligh und Dyer einer Lipidextraktion unterzogen und mittels FIA-FTMS analysiert. 
Die Methode wurde an einer Q Exactive hybrid Orbitrap mit einer maximalen Auflösung 
von 140,000 bei m/z 200 entwickelt. Kurze Messzeiten von weniger als vier Minuten 
und eine automatisierte Datenauswertung unter Verwendung der ALEX-Software und 
selbstprogrammierter Makros in Microsoft Excel ermöglichten einen hohen 
Probendurchsatz.  
 
Die Analyse von Fäkalien verschiedener Probanden ergab eine große Heterogenität 
der Lipidkonzentrationen. In der Mehrzahl der Proben wurden Triacylglycerin- (TG) 
und Diacylglycerin-Spezies (DG) detektiert, welche durch MS2-Spektren verifiziert 
werden konnten. Daher konzentrierte sich die Quantifizierung hauptsächlich auf diese 
beiden Lipidklassen. Die Methodenvalidierung umfasste Experimente zur 
Nachweisgrenze, Linearität, Bewertung von Matrixeffekten, Wiederfindung und 
Reproduzierbarkeit. Die durchgeführten Validierungsexperimente zeigten eine gute 
Reproduzierbarkeit, mit Ausnahme von etwa 10% der Proben, bei welchen ein CV von 
mehr als 15% beobachtet wurde. Die beeinträchtigte Reproduzierbarkeit war auf die 
Probeninhomogenität zurückzuführen und konnte auch durch zusätzliche 
Probenvorbereitungsschritte nicht verbessert werden. Zudem zeigten diese 
Experimente höhere Mengen an DG-Spezies, wenn die Proben in 2-Propanol statt in 
wässriger Lösung homogenisiert wurden, was sich vermutlich auf die Lyse von 
Bakterien und eine erhöhte TG-Lipolyse zurückführen lässt. Diese Effekte waren 
probenspezifisch und untermauerten die hohe Heterogenität der fäkalen Materialien 
sowie die Notwendigkeit einer weiteren Evaluierung der präanalytischen Bedingungen.  
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Eine Messung im negativen Ionenmodus durch Zugabe von Methylamin ergab nur 
sehr niedrige Signale für Lyso-Phospholipide und Glycerophospholipide, welche nicht 
verifiziert werden konnten. Hieraus lässt sich schließen, dass für die Analyse dieser 
Lipidklassen empfindlichere Methoden wie z.B. LC-MS benötigt werden. 
 
Zusammenfassend konnte gezeigt werden, dass FIA-FTMS ein schnelles und 
genaues Verfahren zur Quantifizierung von DG- und TG-Spezies darstellt, welches 
geeignet ist, einen Einblick in das fäkale Lipidom zu geben und dessen Rolle in 
Gesundheit und Krankheit zu entschlüsseln.  
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IV Abstract 
 
The intestinal microbiome plays an important role in human health and disease and 
fecal materials reflect the microbial activity. Thus, analysis of fecal metabolites 
provides insight into metabolic interactions between gut microbiota and host organism.  
In this work, we applied flow injection analysis coupled to Fourier transform mass 
spectrometry (FIA-FTMS) to identify and quantify lipid species in human fecal samples 
in high throughput. Fecal homogenates were subjected to lipid extraction according to 
the protocol by Bligh and Dyer, and analyzed by FIA-FTMS. The method was 
developed using a Q Exactive hybrid Orbitrap with a maximum resolution of 140,000 
at m/z 200, a short analysis time of less than four minutes and an automated data 
evaluation using the ALEX software and self-programmed macros in Microsoft Excel.  
 
The analysis of different subjects revealed a vast heterogeneity of lipid species 
abundance. The majority of samples displayed prominent signals of triacylglycerol 
(TG) and diacylglycerol (DG) species that could be verified by MS2 spectra. Therefore, 
we focused on the quantification of TG and DG. Method validation included limit of 
quantification, linearity, evaluation of matrix effects, recovery, and reproducibility. The 
validation experiments demonstrated the suitability of the method, with exception of 
approximately 10% of samples in which we observed CVs higher than 15%. Impaired 
reproducibility was related to sample inhomogeneity and could not be improved by 
additional sample preparation steps. Additionally, these experiments demonstrated 
that, compared to aqueous specimens, samples containing isopropanol showed higher 
amounts of DG, presumably due to lysis of bacteria and increased TG lipolysis. These 
effects were sample-specific and substantiate the high heterogeneity of fecal materials 
as well as the need for further evaluation of pre-analytic conditions.  
Despite optimization of ionisation by addition of methylamine FIA-FTMS of fecal lipid 
extracts in negative ion mode revealed low signals for lyso-phospholipids and 
glycerophospholipids that could not be verified. This suggests that analysis of these 
lipid classes requires more sensitive methods like LC-MS.  
 
In summary, FIA-FTMS offers a fast and accurate tool to quantify DG and TG species 
and is suitable to provide insight into the fecal lipidome and its role in health and 
disease.  
1. INTRODUCTION 
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1. Introduction 
 
Lipids are an important class of biomolecules in living organisms. Due to their 
hydrophobic nature, lipids provide the ability to separate living entities from their natural 
surroundings. They originate entirely or in part from carbocation-based condensations 
of isoprene units and/or from carbanion-based condensations of thioesters (1). The 
lipid species possess different aliphatic chains and various polar head groups which 
are differentially connected to the head groups. The aliphatic chains of lipids vary in 
the number of carbon atoms, degree of unsaturation, location of double bonds, and 
potential branches (2). Besides the important function of energy storage, lipids serve 
as building blocks in cellular and subcellular membranes, and as signaling molecules 
(3). Cellular lipids are very dynamic and highly complex. At the level of attomole to 
nanomole of lipids per mg of protein tens to hundreds of thousand possible molecular 
lipid species could be present in the cellular lipidome (4). Therefore, the reliable and 
accurate quantification of lipid species is important (5). Since lipids play a crucial role 
in many biological processes, any imbalance in sensing and signaling pathways can 
cause cardiovascular disease, neurodegenerative diseases, and type 2 diabetes 
mellitus by promoting atherosclerosis and chronic inflammation (6, 7). Additionally, 
lipids are involved in basic processes essential for tumor development, for example, 
cell growth, proliferation, differentiation, and motility (8).  
Lipids play a role in the last step of the “omic” cascade in which metabolome is 
gradually developed from genome via transcriptome and proteome (9). Lipidomics, a 
subgroup of metabolomics, is a relatively new disciplinary research field due to the 
inherent chemical complexity of the lipidome and the consequent challenges 
associated with analysing it (10). Within the last decade, the number of publications 
has increased rapidly, by a factor of 7.7 according to Web of Science, which makes it 
one of the fastest growing research fields (10). Lipidomics has recently emerged 
because of rapid advances in developing new mass spectrometric protocols and 
techniques due to its sensitivity and specificity (11). Therefore, dynamic changes of 
lipids during physiological or pathological processes can be determined by analyzing 
lipid structures, mass levels, cell functions, and interactions in a spatial and temporal 
fashion (2). Over the last decades, several mass spectrometric lipidomic methods with 
clinical and scientific application have been adapted (12-14). 
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1.1 Lipid Categories 
 
Lipids, a heterogeneous pool of compounds, contain either fatty acyl/alkyl, 
sphingosine, or isoprene moieties as their hydrophobic building block. Lipid Maps 
consortium has classified lipids into eight categories in 2005. Based on the publication 
of Fahy et al. (1), lipid species are divided into following categories: fatty acyls (FA), 
glycerolipids (GL), glycerophospholipids (GP), sphingolipids (SP), sterol lipids (ST), 
prenol lipids (PR), saccharolipids (SL), and polyketides (PK). Sterol and prenol lipids 
are derived from the condensation of isoprene subunits, whereas other lipid classes 
are synthesized from ketoacyl subunits (15). Each of the eight lipid categories 




Figure 1.1: Examples of the eight lipid categories according to the International Lipids 
Classification and Nomenclature Committee. Reprinted with permission from Springer 
Nature and Creative Common Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/). Copyright Züllig, T.; Trötzmüller, M.; 
Köfeler, H.; 2020 (16).  
 
 
This chapter will briefly introduce the mammalian lipid categories FA, GL, GP, SP, and 
ST (Figure 1.1). 
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1.1.1 Fatty Acyls 
 
Fatty acyls (FA) are carboxylic acids, which consist of a hydrocarbon chain and a 
terminal carboxyl group (17). They are synthesized by chain elongation of acetyl-CoA 
with a malonyl-CoA or methylmalonyl-CoA group (1), which imparts a hydrophobic 
character to the overall structure. Whereas most saturated and monounsaturated fatty 
acyls can be synthesized by human themselves, most polyunsaturated fatty acyls need 
to be obtained through diet, e.g. n-6 linoleic acid (LA) and n-3 α-linoleic acid (ALA) 
(18). Fatty acyls serve both as energy storage and building blocks for complex lipids, 
e.g. as components of glycerophospholipids. Their biological activities influence a 
range of processes and functions in living organisms, cell and tissue metabolism, and 
responsiveness to hormonal signals. Additionally, as components of 
glycerophospholipids fatty acyls regulate membrane structure and as oxidized 
products they control intracellular signaling pathways and gene expression (19). 
Through these effects, they form a key category of metabolites and influence all 
aspects in health and disease (19, 20). Depending on their chemical structure, fatty 
acyls can be divided into different subclasses, for example fatty alcohols or fatty esters. 
Fatty acids, which include saturated and unsaturated species, represent one of the 
most common subclasses of fatty acyls. Furthermore, they can be classified according 
to their number of carbon atoms and number, position, and stereochemistry of the 
double bonds. In principle, FAs are classified according to their number of carbon 
atoms and double bonds. Short-chain fatty acids (SCFA) contain less than 6 carbons, 
medium-chain fatty acids (MCFA) possess between 6 and 12 carbons, and long-chain 
fatty acids (LCFA) consist of more than 12 carbon atoms. The degree of unsaturation 
depends on the number of double bonds. FA species are described as being 
unsaturated when they have no double bond, whereas monounsaturated FAs contain 
one double bond, and polyunsaturated FAs have multiple double bonds. In mammals 
most common fatty acids are even numbered and saturated or monounsaturated fatty 
acids with chain lengths of 16, 18, and 20 carbon atoms (21). However, species with 2 
to 36 carbon atoms, including odd-numbered species, can also be found in nature (22). 
Two examples are shown in Figure 1.2. 
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Figure 1.2: Structures of FA 18:2 and 5-HETE from LIPID MAPS®. 
 
 
Catabolism of FA by β-oxidation converts long-chain fatty acids into two-carbon 
acetate which is introduced into the citric acid cycle as acetyl-coenzyme A (acetyl-CoA) 
for energy production (23). Fatty acid metabolism plays an important part in meeting 
the energy demands of the heart, for example in promoting cardiac pathologies or 
protecting the heart from cardiovascular disease (24). Besides that, dysregulation of 
the fatty acid homeostasis can lead to atherosclerosis and various types of cancer. 




Glycerolipids (GL) are a structurally heterogeneous group of lipids that can be 
categorized into different classes depending on the esterification of fatty acyls with 
glycerol. In each of these classes, several subclasses exist due to the differences in 
their ether or acyl linkage, thus leading to a very high number of molecules. All species 
have at least one hydrophobic chain which is linked to a glycerol backbone in an ether 
or ester linkage (26). Depending on the esterification of one, two or three fatty acyls 
with glycerol, the lipid classes are referred to monoacylglycerol (MG), diacylglycerol 
(DG), and triacylglycerol (TG), respectively (20). The structures of these lipid classes 
are shown in Figure 1.3. 
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Figure 1.3: Structures of mammalian glycerolipid species MG 16:0, DG 34:1 and 
TG 52:3 from LIPID MAPS®. 
 
Glycerolipids play prominent roles in physiology and human disease; they are 
associated with fat storage, metabolic disorders, and cancer survival (27). Whereas 
there is only little information available on the function of MG, DG is a neutral lipid 
involved in the synaptic vesicle cycle (28) and in the formation of membranes (29). 
Additionally, post prandial hyperlipidemia, a risk marker for cardiovascular disease, is 
known to be improved by DG species (30).  
The chemical structure of DGs is versatile. Two (different) fatty acids are esterified to 
the glycerol backbone and can occur as three different stereo- or regioisomers, either 
at sn-1/2, sn-2/3 or rac-1/3 position, respectively (31). A schematic depiction of the 
different regioisomers is shown in Figure 1.4. Depending on the fatty acid species 
esterified to sn-1 or sn-3, DGs can be achiral or chiral. They are termed as achiral 
when two identical fatty esters are bound to these positions. If two different fatty acids 
are attached to the glycerol backbone, DG is chiral (31). Due to the stereochemical 
nature of DG isomers, the species have different metabolic and nutritional 
characteristics (32). Several studies demonstrated the physiological and anti-obesity 
effects, in particular of 1,3 DG (33, 34). As such, DG has shown to reduce both body 
weight and visceral fat mass (35). Due to the ability of these lipid species to suppress 
both obesity and post prandial hyperlipidemia, DGs have been increasingly 
incorporated into food products (36, 37).  
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Figure 1.4: Schematic depiction of the different forms of regioisomers of diacylglycerol. 
Reprinted with permission from Creative Common Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/). Copyright Eichmann, T.; Lass, A.; 2015 
(31). Illustration has been modified.  
 
In adipose tissue of higher eukaryotes TGs serve as the major energy storage 
molecule (38), since they provide much more energy during oxidation than 
carbohydrates or proteins (39). In addition to storing energy, the synthesis of TGs 
protects the cell from the potentially toxic effects of excess FA. However, excessive 
accumulation of TGs is associated with human diseases, such as diabetes mellitus, 
obesity, and hepatic steatosis. Triglycerides mainly exist as triacylglycerol species in 
nature, however, there is also a small amount of ether-linked triglyceride species (40), 
which do not only differ in chain length and degree of saturation but also in chemical 
and physical properties (41). As already mentioned for the DG species, there are also 
different stereo- or regioisomers of TG. This species contain a chiral center and, 
therefore, optical activity, when two primary hydroxyl groups are esterified with different 
fatty acids (42). However, analysis of TG composition is very challenging due to the 
tremendous amount of individual species caused by the number of possible FA 
combinations on the glycerol backbone. The knowledge of the TG structure, especially 
the fatty acids linked with the glycerol backbone, is of great importance for 
understanding the lipid metabolism and e.g. the production of food products (43). 
Additionally, specific effects on health are obtained, which can be assessed by a 
deeper insight into the individual TG types. Most remarkably, there is an association 
between saturated TGs with short carbon chains and insulin resistance (44). 
Regarding TGs, many studies mainly deal with fats and oils originating from plants or 
animals. Composition and structure of TG species determine the functionality of these 
fats and oils as food ingredients and their physiological effects as part of the human 
diet (43). Vegetable oils provide 25% of the food calories in industrialized countries 
(45). Humans consume approximately 90-120 grams of fat per day. More than 95% 
1.1 LIPID CATEGORIES 
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are absorbed (46). However, TG species cannot be absorbed directly by the 
gastrointestinal (GI) tract. Digestion of TG begins in the stomach. Approximately 15% 
of the fatty acids from TGs are released by preduodenal lipases, gastric lipase or 
lingual lipase (47). The absorption of dietary fats mainly takes place in the small 
intestine. Therefore, the fatty acids at position 1 and 3 of the glycerol backbone must 
be removed by pancreatic lipase. The resulting FAs and MGs can then be absorbed 
via active transport and/or diffusion processes by small intestinal enterocytes. After 
absorption FAs and MGs are then used to synthesize TGs within the enterocytes. 
Synthesized TGs are combined with cholesterol, cholesterol esters and apolipoprotein 
B48 to form chylomicrons (48, 49). Diabetes mellitus, obesity and excessive alcohol 
consumption can lead to an increase of TGs in the human blood, which is called 
hypertriglyceridemia. In rare cases hypertriglyceridemia can cause life-threating acute 




Glycerophospholipids (GPL) are amphiphilic molecules and consist of a hydrophilic 
head group. This head group is connected by a phosphate ester at one of the terminal 
positions of the glycerol backbone and one or two hydrophobic fatty acids are ether- 
or esterified at the remaining hydroxyl positions (51). In all living organisms, GPLs play 
a key role in cellular membrane and have important functional and structural properties, 
e.g. as cellular messengers or enzyme activators (42). Due to their different polar head 
groups, GPLs can be divided into different classes. The main subclasses are 
phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), phosphatidylinositol (PI), and phosphatidylserine (PS), 
which are shown in Figure 1.5.  
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Figure 1.5: Structures of different glycerophospholipid species from LIPID MAPS®. 
 
Glycerophospholipids are also defined by a stereospecific numbering (sn) convention, 
which indicates the relative positions of head group and acyl chain attachment. The 
modification of glycerol leads to chirality around the central carbon (52) as it is 
described for glycerolipids. In eukaryotic cells, the fatty acyl chains are typically 
attached at the sn-1 and sn-2 positions, whereas the head group is esterified at the 
sn-3 position of the glycerol backbone. In GPLs, two different fatty acyl chains allow 
two regioisomers with alternating substitutions at the sn-1 and sn-2 positions. Various 
studies showed that unsaturated fatty acyl chains were preferably esterified at the sn-2 
position (53). However, there is increasing evidence that both sn-positional isomers 
are frequently present. Different biophysical and chemical properties of regioisomers 
were observed. Therefore, the research suggests that these isomers have different 
functions in nature (54). GPLs make up most of the lipids of cell membranes, consisting 
of a multiplicity of individual protein and lipid species. Usually, these membranes are 
composed of two layers of lipid molecules and therefore play an important role in 
determining the physicochemical properties. The GPL composition can be very 
different for diverse cell types, organelles, and inner or outer membrane leaflets, 
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respectively (55). The inner side of the outer membrane mainly contains PE, PG, and 
the respective monoacyl-glycerophospholipids lyso-PE and lyso-PG (56). The 
introduction of polyunsaturated fatty acids into the glycerophospholipids of the 
membrane is promoted by the deacylation-reacylation cycle. This process is also 
known as Lands-Cycle and includes the following enzymes: phospholipase A2, acyl-





The lipid class of sphingolipids (SP) is defined by a long chain sphingoid base which 
may be linked to a fatty acid at C2 position via an amide bond. Sphingoid base d18:1 
is the most common of these backbones in mammalian cells. It varies in chain length, 
degree of saturation (58, 59) and number of hydroxyl groups (60), e.g. sphinganine 
((2S,3R)-2-aminooctadecane-1,3-diol, which is fully saturated, and phytosphingosine 
((2S,3S,4R)-2-aminooctadecane-1,3,4-triol), which is also fully saturated and has a 
third hydroxy group (58, 59). 
The simplest class of SP are ceramides (Cer) which are formed by adding an acyl 
chain to the amino group of the sphingoid base. Sphingolipids can also be 
distinguished by the type of head group that replaces the hydroxyl group of the carbon 
in the 1-position (61). Phosphosphingolipids, for example, contain a phosphodiester 
bond at the head group and glycosphingolipids a β-glycosidically bonded sugar, 
whereas sphingomyelin (SM) is generated by the addition of a phosphocholine head 
group (62). Thus, sphingomyelins (SM), ceramides (Cer), and hexosylceramides 
(HexCer) differ by their head groups but frequently contain a dihydroxy C18 sphingosine 
base (62) (Figure 1.6).  
C16-, C18-, and C24-ceramides are most commonly found in mammals. They provide 
a variety of unique properties (61, 63, 64), e.g. they serve as precursors to form either 
phosphor- or glycosphingolipids by adding diverse head groups. Ceramides are 
hydrophobic lipids which increase the molecular order of phospholipid-containing 
membranes (65) although they are only minor components within these membranes 
(66). In the Golgi apparatus ceramides can be converted into SM or glucosylceramide 
(GlcCer) (61). Sphingolipids play an important role in cell signaling and plasma 
membrane structure. They comprise a broad spectrum of complex lipids and represent 
one of the most important lipid classes in eukaryotic cells (67).  
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Whereas sphingosine-1-phosphate (S1P), for example, plays a crucial role in cell 
survival, cell migration or inflammation (68), Cers mediate many cellular stress 
response including the regulation of apoptosis (69) and cell senescence (70). Various 
biological processes are regulated by sphingolipids, including growth, invasion, 
migration, proliferation and/or metastasis. In the latter case, signaling function can be 
controlled within the cancer cell signal transduction network (71, 72). Ceramide and 
sphingosine formation can be induced by chemotherapy, radiation and/or oxidative 
stress (73). Irregular intracellular apoptotic signal transduction can cause changes in 




Figure 1.6: Examples of mammalian sphingolipids from LIPID MAPS®. 
 
1.1.5 Sterol Lipids 
 
Sterols (ST) are isoprenoid-derived amphipathic biomolecules which play important 
physical and structural roles in eukaryotic cells (75) and thus provide valuable insights 
into the evolution of life (76). All sterols have a common structure which consists of a 
tetracyclic cyclopenta(a)phenanthrene nucleus. Furthermore, some sterols are 
connected to carbon 17 via a side chain (76). Sterol synthesis involves the 
polymerization of the precursors isopentenyl diphosphate (IPP) and dimethylallyl 
pyrophosphate (DMAPP) (75).These lipids can be categorized in sterols, steroids, 
steroid conjugates, secosteroids and bile acids. The most common sterols in plants 
are phytosterols, e.g. campesterol, stigmasterol or sitosterol. In animals and yeast 
cholesterol and ergosterol are predominant (77) (Figure 1.7), respectively. With few 
exceptions (78, 79), sterols are found exclusively in eukaryotes. They are involved in 
various cell functions, e.g. in membrane fluidity and structure, developmental 
regulations or as precursors of hormone and signal molecules.  
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Figure 1.7: Exemplary species of sterol lipid species from LIPID MAPS®. 
 
Cholesterol, which is especially important in mammalian cells, consists of 27 carbon 
atoms. Modification of the side chain or the nucleus allow a variety of different 
structures (76). Cholesterol occurs mainly as cholesteryl esters (CE) which are stored 
in lipid droplets or transported in lipoprotein particles, and as non-esterified free 
cholesterol (FC) in membranes (80). Cholesterol is primarily synthesized from acetyl-
CoA by sequential enzymatic reactions in tissues, especially the liver, adrenal gland, 
brain, ovary, and testis (81). Hydrogenation of sterols leads to the formation of stanols, 
usually by microbes either in animal gastrointestinal tract or in the environment (82, 
83). Due to their low water solubility and their ability to bind to organic material, 
5β-stanols are particularly useful as direct biomarkers for animal feces (84). The so-
called stanol fingerprint, i.e. its distribution in the fecal material, identifies a certain 
mammalian species on the basis of various processes, including the basis of their diet 
(primary sterol intake), the ability to biosynthesize endogenous sterols (secondary 
sterol intake) and the way how they biohydrogenate sterols and convert them into 
stanols with the help of bacteria of the digestive tract (85). Furthermore, a distribution 
of microbial cholesterol-to-coprostanol conversion in human populations is bimodal, 
with a minority of low metabolizers and many high metabolizers, i.e. almost complete 
cholesterol conversion. The efficiency of cholesterol conversion is mainly dependent 
on the abundance of cholesterol-lowering bacteria (86). In addition, a correlation 
between cholesterol-lowering activity in the human gut and the overall structure of fecal 
microbial community has been established (87).  
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1.1.6 Nomenclature 
 
In this work, lipid nomenclature is based on a comprehensive classification system for 
lipids presented by the Nomenclature Committee and International Lipid Classification 
in 2005 (1), which was updated in 2009 (88). Practical shorthand notation of lipid 
structures derived from mass spectrometry (MS) approaches have been developed in 
2013, which enables correct and concise reporting of data and their deposition in 
several databases (89). The simplest way of describing the structure is to write the 
total number of carbons followed by the total number of double bonds. For example, 
DG 36:2 describes the lipid class (DG, diacylglycerol), whereas the total number of 
carbon atoms is 36 and the total number of double bonds is 2 in the acyl chains. This 
notation is used as a sum formula and gives no information about the exact 
composition of the fatty acyl chains. To further specify this, various acyl combinations 
are possible, for example DG 18:1_18:1 and DG 18:0_18:2 without specification of sn 
positions using “_” as previously proposed (89). If the sn positions of the fatty acyls are 
known, this would be expressed with the separator “/”, e.g. DG 0:0/18:0/18:2 or 
DG 0:0/18:2/18:0 (sn-1 / sn-2 / sn-3). By using high-resolution mass spectrometry, it is 
possible to obtain a separation between ester bonds and other bond types. An ether 
bond, for example, is indicated by an “O-” in front of the sum of C-atoms of fatty 
acyls/alkyls: DG O-36:2. The letter “P” is used for a proven O-alk-1-enyl-bond, i.e. an 
acid-sensitive ether bond in plasmalogens. More than one “non”-ester bond is 
indicated in front of the bond type as d for di, t for tri, e.g. DG dO-36:2. Positions are 
stated according to ∆-nomenclature in front of the functional groups. Double bond 
position is indicated by a number (geometry unknown) or by the number followed by 
the geometry (Z for cis, E for trans). There are also different abbreviations for functional 
groups: “Me-” for methyl branch, “O-” for keto group, and “OH-” for hydroxyl group (89).  
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1.2 Principles of Mass Spectrometry 
 
Many analytical methods have been developed for accurate identification and 
quantification of lipid species. A common analytical technique is mass spectrometry 
(MS) which has been established in lipidomics in recent years.  
Mass spectrometry is used to quantify known materials, to identify unknown 
compounds and to clarify the structure and chemical properties of various molecules. 
The basic principle of mass spectrometry is to separate and measure ions by their 
specific mass-to-charge ratio (m/z). These ions are detected qualitatively and 
quantitatively by their respective m/z and abundance. The instrument consists of three 
major components: (I) an ion source which produces gaseous ions from the substance, 
(II) a mass analyzer resolving the ions into their characteristic mass components 
according to their m/z, and (III) a detector system which detects the ions and records 
the relative abundance of each species. The most commonly applied methodologies 
in lipidomics involve electrospray ionization (ESI) sources and triple quadrupole 
analyzers (90). There are also other types of mass analyzers, for example, magnetic 
(B) / electric (E) sector mass analyzer, linear quadrupole ion trap (LIT), time-of-flight 
mass analyzer (TOF), ion cyclotron resonance mass analyzer (ICR), and orbitrap. All 
these mass analyzers use dynamic or static magnetic or electric fields to separate ions, 
and operate according to two fundamental physical laws, e.g. Lorentz force law and 
Newton’s second law of motion (91-93). The analyzers differ by analysis speed, mass 
accuracy, mass range, mass resolution, and sensitivity.  
Mass spectrometry allows to determine the elemental composition, molecular weight 
and, using MS2, position of branching and the type of substituents in the lipid structure. 
Due to its high accuracy, sensitivity, specificity, and throughput, MS has become a 
preferred method for lipid analysis. 
Regarding this thesis, lipid analysis was performed by flow injection Fourier transform 
mass spectrometry. A hybrid quadrupole Orbitrap mass spectrometer Q Exactive is 
coupled to a heated electrospray ionization source and a PAL autosampler. The 
following chapters will describe the applied technique in more detail.  
 
1.2.1 Electrospray Ionization 
 
In recent years, electrospray ionization (ESI) has emerged as an important “soft” 
ionization technique which produces intact ions. This technique represents a sensitive, 
robust, and reliable method for the investigation of large, non-volatile, and thermally 
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unstable molecules, such as those found in biological systems, e.g. in lipids, peptides, 
or proteins. The samples can be measured in femto-mol quantities in microliter sample 
volume. High voltage is applied to spray the sample solution into the gaseous phase 
by the ESI needle. This process comprises three steps: (I) atomization of a fine spray 
of charge droplets, (II) solvent evaporation, and (III) ejection of ions from the highly 
charged droplets (94) (Figure 1.8). The solvent slowly evaporates, often supported by 
a neutral carrier gas such as nitrogen which increases the surface charge density and 
reduces the droplet radius. These droplets are continuously dissolved by repulsion of 
similar charges (“Coulomb explosion”) into smaller droplets as they have reached the 
Rayleigh limit. Droplets are then electrically charged on the surface. Depending on 




Figure 1.8: Schematic illustration of an ESI process. Reprinted with permission from 
Thermo Fisher Scientific. Copyright 2008 Thermo Fisher Scientific. 
 
 
1.2.2 Quadrupole Mass Analyzer 
 
One of the mass analyzers used for ESI is a quadrupole mass spectrometer which was 
invented by Wolfgang Paul in the early 1950s (96). The main principle of ion separation 
in MS is based on the movement of ions through a magnetic or electric field, whereby 
the movement is influenced by their m/z ratio. The quadrupole mass analyzer consists 
of four parallel hyperbolic/circular metal rods. Opposite rods are electrically connected. 
A direct current (DC) voltage and a radio frequency (RF) of the same amplitude and 
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sign are applied to the diagonally arranged rods. The rod pairs, however, differ in their 
polarity. By means of an electric field, the ions are moved forward in the z-direction 
with an oscillating movement in the x-y-plane. The applied ratio of voltages can be 
used to control the oscillation amplitude to allow ions of a specific m/z ratio to finally 
reach the detector. Vibration amplitudes of unwanted ions can be large and unstable. 
Hitting the metal rods these ions are neutralized and do not reach the detector, see 
Figure 1.9. Quadrupole mass analyzers are robust, economical, physically small and 






Figure 1.9: Schematic illustration of a quadrupol mass analyzer.  
 
 
1.2.3 Orbitrap Mass Analyzer 
 
The origins of the orbitrap analyzer trace back to the year 1923. Kingdon discovered 
the principle of orbital trapping by placing a charged wire on a closed cylindrical metal 
can (97). In the year 2000, Alexander Makarov published the concept of an orbital 
trapping device for the application in mass analysis. Unlike the previous attempts, the 
central electrode was not used as a thin wire but as a solid metal electrode (98). The 
orbitrap mass analyzer essentially consists of three electrodes: two cup-shaped outer 
electrodes face inwards and a spindle-shaped central electrode is aligned along the 
axis. The outer electrodes are electrically insulated by a hairline gap which in turn is 
secured by a dielectric ring. The central electrode holds the trap together and aligns it 
via the dielectric end-spacer. The applied electric field consists of a quadrupole field of 
the trap, e.g. a standard trap or a high field compact trap, and an additional logarithmic 
field of the cylindrical capacitor (99, 100). Applying voltage between the outer and 
central electrodes, stable ion trajectories induce a harmonic oscillation along the z-
axis. The radial component of the field simultaneously pulls the ions towards the central 
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electrode. Ions with the same m/z ratio oscillate in-phase along the z-axis for 




Figure 1.10: Orbitrap mass analyzer showing a stable spiral trajectory of an ion 
between the central electrode and the split outer electrodes. Reprinted with permission 
from Thermo Fisher Scientific. Copyright 2008 Thermo Fisher Scientific. 
 
An ion trap is mounted outside the analyzer to produce stable ions. Using the principle 
of “electrodynamic squeezing” (101) the ions are captured and enter the trapping field 
by a steady increase of the electric field strength. The outer electrodes remain at a 
fixed potential, whereas the potential at the central electrode is lowered. Once the ions 
enter the field through this potential gate, they cannot escape at the point of entry, as 
the trapping potential forms a potential barrier until they return to the gate. To ensure 
the widest possible range of trapped m/z, a rise-time of the field, typically 30 – 50 µs, 
is chosen (102).  
To achieve high mass resolutions orbitrap instruments apply image current detection 
using Fourier transform Mass Spectrometry (FTMS), using two split halves of outer 
electrodes for detection and a differential amplifier for amplification. The application of 
FT determines the frequency of the harmonic oscillations and allows the calculation of 
the m/z ratios of the subjected ions (103).  
 
1.2.4 Tandem Mass Spectrometry 
 
One of the most used mass analyzers in lipidomics is the triple quadrupole mass 
analyzer (QqQ), which is commonly used in MS/MS. It consists of three quadrupoles 
connected in series (Q1 – Q3). The following arrangement is most frequently used: Q1 
filters for a specific m/z ratio (precursor ion); Q2, a collision cell, is filled with an inert 
gas like argon or nitrogen; and Q3 analyses the fragment ions induced by collision with 
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the gas molecules, shown in Figure 1.11. Both Q1 and Q3 can be used either in SIM 




Figure 1.11: Schematic illustration of a triple quadrupole mass spectrometer (104). 
Modified with permission of Copyright Clearance Center’s Rightslink® service. 
Copyright 2014 Elsevier Inc. 
 
The following operation modes are commonly applied: Product ion scan, precursor ion 
scan, neutral loss scan, and selected reaction monitoring (SRM) or multiple reaction 
monitoring (MRM). In a product ion scan, a precursor ion is selected in Q1, followed 
by collision induced fragmentation, whereas Q3 scans for resulting fragment ions. This 
mode provides largely substance-specific structural information. In a precursor ion 
scan, the precursor masses are scanned in Q1, a fragment ion is selected in Q3. 
Groups of substances with specific characteristic structures or fragmentation reactions 
can be identified. In a neutral loss mode, Q1 and Q3 are scanned with a fixed offset 
between both mass analyzers. It can be used to identify all precursor ions with a loss 
of a defined mass. In selected reaction monitoring, both mass analyzers are set to 
selected masses (105, 106).  
 
1.2.5 Q Exactive Hybrid Orbitrap Mass Spectrometer 
 
A Q Exactive Orbitrap mass spectrometer combines a high resolution Orbitrap mass 
analyzer and a high-performance quadrupole for precursor selection. 
The Q Exactive hybrid quadrupole Orbitrap mass spectrometer mainly consists of an 
ion source, a stacked ring ion conductor (S-lens), a bend flatapole, a quadrupole mass 
filter, a curved linear trap filled with nitrogen (C-trap), a higher energy collisional 
dissociation (HCD) cell and an orbitrap mass analyzer (Figure 1.12).  
The samples can be introduced into the ion source by various methods, while the 
injection flatapole transfers the ions from the source to the quadrupole. In the C-trap, 
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the kinetic energy of the injected ions dissipates by collision with the nitrogen 
molecules, bundles them on the trap axis and then injects them orthogonally to the z-
axis of the orbitrap mass analyzer to obtain a mass spectrum. Furthermore, the ion 
bundles can be guided through the C-trap into the HCD cell and perform MS/MS 
experiments in combination with the quadrupole mass filter.  
 
 
Figure 1.12: Schematic illustration of a Q Exactive Orbitrap mass spectrometer. 




To investigate samples in high throughput, shotgun mass spectrometry of biological 
samples is routinely applied (107). A commonly used technique for all lipidomic 
approaches is a high-resolution FTMS instrument chip-based nano-ESI (108-111). In 
this thesis, a Q Exactive hybrid Orbitrap mass spectrometer was used for lipid analysis, 
using a conventional LC pumping system to infuse raw lipid extracts of feces.  
 
1.2.6 Direct Infusion Mass Spectrometry 
 
In direct infusion mass spectrometry (DIMS), the sample is pumped directly into the 
mass spectrometer without any prior separation. Therefore, the liquid sample is placed 
in a syringe. A syringe pump is used to ensure a regular flow of liquid. The injection of 
a liquid sample into a moving, non-segmented continuous carrier stream of a suitable 
liquid is called flow injection analysis (FIA) (112). FIA frequently uses an HPLC system 
that injects the analytes directly into the ionization source of the mass spectrometer 
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without prior chromatographic separation (FIA-MS) (113). Flow injection is coupled to 
an autosampler (114). 
Direct infusion is best suited for pure samples or simple mixtures and should be free 
of contaminating factors that could otherwise interfere with the measurement, such as 
high contents of non-volatile salts or detergents. Direct infusion mass spectrometers 
are often equipped with electrospray ionization. In this process, intact molecular 
masses of analytes can be detected or fragmented. This facilitates the identification of 
the so-called “fingerprint” of chemicals and relies on the accurately determined masses 
on MS level or specific fragment ions in MS/MS spectra (115, 116).  
In DIMS, which is also called “shotgun”, the lipid composition and concentration of 
analytes does not change over time, which simplifies the quantification of the species 
(6). Advantages of direct infusion are its simplicity, high reproducibility, and the 
constant electrospray conditions, e.g. matrix, solvent composition, and sample 
concentration, which could influence the ionization of the analytes without significantly 
affecting sensitivity, precision, and accuracy (117, 118). However, disadvantages of 
this technique are the ion suppression effect and the inability to distinguish many 
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1.3 Mass Spectrometric Lipid Analysis  
 
Analysis of lipids is either based on the separation of different lipid categories by 
chromatographic separation or on so-called shotgun-Lipidomics which essentially 
analyze all lipid classes without prior chromatographic separation (119). However, a 
more detailed elucidation of structural properties of lipids requires the use of MS/MS 
analysis. This chapter describes the extraction of lipids as well as the fragmentation 
behavior of DG and TG with respect to the acyl chain and head group elements.  
 
 
1.3.1 Extraction of Lipids 
 
In Lipidomics it is important to perform an extraction of lipid species to obtain an 
accurate profile of lipidomes in a sample of interest. Each extraction method serves 
two main purposes. On the one hand, the complexity of the sample is reduced by 
eliminating unwanted non-lipid compounds such proteins. A positive side effect is the 
reduction of impurities, this leads to a less contaminated mass spectrometer and thus 
to less instrument downtime due to cleaning and maintenance. On the other hand, the 
lipids of interest accumulate during extraction, which in turn leads to an improved 
signal-to-noise ratio (16). In principle, there are two different extraction possibilities: 
liquid-liquid (LLE) or solid-phase (SPE) extraction. SPE is a very specific sample 
preparation technique and provides highly enriched samples with low contamination. 
However, as the number of analyzed lipid classes increases, this extraction protocol 
becomes very complex and challenging. If many lipid classes need to be analyzed in 
high throughput SPE is unsuitable. It can certainly be a useful method if only a few 
samples with a very high coverage of the lipid species need to be analyzed (16). In 
contrast, liquid-liquid extraction is the most commonly used sample preparation 
technique in lipidomics. Organic solvents such as chloroform/methanol (CHCl3/MeOH) 
or methyl-tert-butyl ether (MTBE) are typically used for this purpose. Two of the most 
common treatments are based on the protocols by Folch (120) and Bligh and Dyer 
(121) and consist of a ternary mixture of chloroform, methanol, and water. Other 
common LLEs are MTBE extraction, single-phase extraction, butanol/methanol 
extraction (BUME) and 3-phase extraction. Those are listed in Table 1.1. 
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Table 1.1: Comparison of different LLEs regarding the extraction solvents used, the 
phase separation, the type of detectable lipids, and the advantages and disadvantages 
of the divers extraction methods (16). 
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1.3.2 Mass Spectrometric Analysis of Lipids 
 
Over the last decades several mass spectrometric lipidomic methods with scientific 
and clinical application have been developed (12-14). A common way to reduce the 
complexity of lipid extracts for MS-based approaches is to use chromatographic 
separation, especially gas (GC) and liquid chromatography (LC) (122-124). Shotgun 
lipidomics, as described above, is a direct infusion-based approach without any 
separation prior mass spectrometric analysis. The development of high-resolution 
mass spectrometry led to an increasing interest in the application on MS level. The 
technical simplicity and rather short measurement times allow the detection of several 
lipid classes in a single analysis. Nowadays, shotgun MS analysis of biological samples 
is routinely used for high-throughput analysis of samples (107). 
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A detailed structural analysis of the lipid species requires MS/MS analysis using a 
tandem mass spectrometer. This is a very helpful and informative technique with 
respect to the acyl chain and head group elements for most lipid classes (125-127).  
 
Collision Induced Dissociation (CID) of ammonium adducts [M+NH4]+ of diacylglycerol 
and triacylglycerol in positive ion mode results in fragment ions corresponding to the 
loss of 17,0266 Da (i.e. the loss of ammonia) combined with a charge-remote loss of 
FA moieties as fatty acids (RCOOH + NH3), e.g. FA 16:1 has a neutral loss (NL) of 
m/z 271, FA 18:1 a neutral loss of m/z 299 and FA 18:0 a NL of m/z 301. These ions 
provide information about the acyl composition of both lipid classes and therefore are 
denoted as molecular lipid fragments (MLF) (128). For DG species a NL of water 
together with ammonia from an [M+NH4]+ ion is typical and denoted “-DG(35)” as lipid 




Figure 1.13: Fragmentation of diacylglycerol (a) and triacylglycerol (b) regarding their 
acyl chain composition. The dotted lines indicate the most labile bonds from which 
fragmentation most frequently occurs.  
Displayed are a) DG with two acyl chains and one OH group (here 1,3 DG) and b) TG 
comprising three acyl (FA1 to 3) chains.  
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1.4 Lipid Analysis of Feces 
 
In recent years, the interest in intestinal microbiome as well as the analysis of lipids in 
feces has increased significantly. The intestinal microbiome actively influences host 
functions and therefore plays an important role in human health and disease. 
Homogenization of fecal samples is of great importance for lipid analysis, as the 
sample material is very heterogeneous and thus more difficult to analyze. In this 
chapter, microbiome, feces, and homogenization are described in detail.  
 
 
1.4.1 Microbiota and Feces 
 
The human body, including the intestine, skin and other mucosal environments, is 
colonized by an enormous number of commensal, symbiotic and pathogenic 
microorganisms, collectively referred to as microbiomes, and is estimated to consist of 
3 × 1013 eukaryotic cells and 3.9 × 1013 colonizing microorganisms (130). These 
microorganisms contain trillions of microbes with more than 700-1000 different species 
of bacteria in the intestine (131). It is estimated that 10 different phyla contribute to the 
functional role of the intestinal microbiome, with Firmicutes and Bacteroidetes being 
the most dominant phyla. The neutral pH and the weakly basic environment make the 
large intestine the most densely populated area of bacteria in the GI tract, with 
approximately 1012 bacteria/g. In the less acidic small intestine, on the other hand, only 
103 bacteria/g can be found (132). 
It is now generally accepted that the gastrointestinal system, in particular the intestinal 
microbiome, actively influences host functions including nutritional responses, 
immunity, medication, and metabolism, and thus plays an important role in human 
health and disease (133). Microbial activity is reflected in fecal materials that contain 
unabsorbed metabolites including lipid species. Consequently, analysis of fecal 
metabolites provides an estimate of metabolic interaction between gut microbiota and 
host (134). These microbe-host interactions are impaired by the intestinal microbial 
ecosystem resulting from changes in lifestyle during industrialization, including 
important shifts in dietary habits, improved hygiene, and access to medication (e.g. 
antibiotics) (135). To identify subtle metabolic variations induced by dietary alterations 
and to characterize the metabolic impact of variations of the gut microbiota, metabolic 
profiling gained increasing interest over the last decade.  
The intestinal microbiome can influence human behaviour through a bi-directional 
communication pathway between the GI tract and the central nervous system, namely 
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the intestinal-brain axis. This is achieved by a microbiome-mediated production of 
molecules, such as serotonin and γ-aminobutyric acid (GABA), which have neuroactive 
effects. Along the GI tract there are nutrient receptors and enteroendocrine cells 
(EECs) that interact with microbial metabolites. For mechanisms such as the regulation 
of appetite and insulin secretion, the interactions with EEC receptors are crucial (136). 
Recent studies show that bacterial proteins act locally in the intestine with a short-term 
effect on saturation and thus influence the appetite-regulating pathways (137).  
Feces are composed of water, proteins, bacterial biomass, fat, and indigestible food 
components, e.g. fibres. Fat contained in feces is a heterogeneous mixture of different 
lipids; it constitutes 8-16% of the dry weight of the feces (138-140) and 2-8% of the wet 
weight (141-145). Fat found within feces originates from bacteria as well as from the 
undigested remains of dietary lipids (146). Non-/esterified fatty acids represent 
approximately 60-70% of this fat, unsaponifiable material accounts for 20-30% (147).  
 
 
1.4.2 Lipid Analysis of Fecal Samples 
 
Human feces contain, depending on diet and metabolism, different amounts of 
triacylglycerol (TG) and diacylglycerol (DG). This has been frequently studied in the 
context of steatorrhoea (148) and colon cancer (149). 
Homogenization is an important step in processing tissue samples, cells or feces. 
Whereas homogenization is not a problem for bioliquids, it is currently still a challenge 
for solid sample material. Homogenization makes lipids from all parts of the sample 
material accessible to extraction solutions. Limited solvent accessibility of the samples 
can result in significantly distorted lipid profiles (16). The homogenization of feces is 
still difficult at this stage. An accepted protocol does not exist yet. Different working 
groups vortex the sample material in phosphate buffer saline (PBS) (150), whereas 
others homogenize for example with the help of bead beating (151). Homogenization 
is a prerequisite for optimal lipid extraction and is often performed manually (152). 
Lipidomic methods nowadays offer a wide range of possibilities to analyze lipid species 
profiles of biological materials (153). However, only a few methods are available to 
study the lipidome of fecal material (134, 154, 155). Most of the described approaches 
focus on the identification and quantification of selected lipid classes like fatty acids 
(156, 157), bile acids (158), and sterols (124). In this thesis we evaluate and validate 
a method for identification and quantification of DG and TG species of human fecal 
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material using flow injection analysis (FIA) coupled to Fourier transform mass 
spectrometry (FIA-FTMS). 
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1.5 Objective of this Work 
 
Main goal of this PhD thesis was to develop a method for the identification and 
quantification of lipid species of human fecal material using flow injection analysis (FIA) 
coupled to Fourier transform mass spectrometry (FIA-FTMS). Method development 
included sample homogenization, lipid extraction, instrumental method, data 
validation, and data evaluation in an untargeted approach. Various homogenization 
methods were tested. The stability of fecal material after sample collection and the 
influence of material consistency were evaluated. Fecal homogenates were subjected 
to lipid extraction according to the protocol by Bligh and Dyer. A Q Exactive hybrid 
Orbitrap high resolution mass spectrometer was used for lipid analysis, equipped with 
a conventional LC isocratic pumping system coupled to a heated electrospray 
ionization (ESI) source to infuse raw lipid extracts of feces.  
Method validation included limit of quantification, linearity, evaluation of matrix effects, 
recovery, and reproducibility. Data evaluation contained the identification of detected 
species using MS2 spectra.  
 
The developed method should be accurate and reproducible as well as fast to allow 
high throughput of samples and to be applicable to fecal samples of clinical and 
scientific studies. 
2. MATERIALS AND METHODS 
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Methanol, ethanol absolute (EMSURE), and acetonitrile were obtained from Merck 
(Darmstadt, Germany), chloroform, 2-propanol, and hexane from Roth (Karlsruhe, 
Germany). All solvents were HPLC grade. Ammonium formate, methylamine solution 
40 wt % in H2O, methylamine solution 33 wt % in EtOH, trimethylamine solution 
45 wt % in H2O, trimethylamine solution 31-35 wt % ~ 4.2 mol/L in EtOH, sodium 
dodecyl sulfate (SDS), acetyl chloride of the highest analytical grade available, and a 
certified fatty acid methyl ester (FAME) mix (Supelco 37 component FAME mix) were 
ordered from Sigma-Aldrich (Taufkirchen, Germany) and isooctane (2,2,4-
trimethylpentane) > 99% from Honeywell (Seelze, Germany). All chemicals and 
standards were of high purity grade for analysis (> 95%).  
Glycerolipid standards were purchased from Larodan (Solna, Sweden): Diarachidin 
(DG 20:0/20:0), Dinonadecanoin (DG 19:0/19:0), Dilinolenin (DG 18:3/18:3), Dilinolein 
(DG 18:2/18:2), 1,2-Distearin (DG 18:0/18:0), Triarachidin (TG 20:0/20:0/20:0), 
Trinonadecanoin (TG 19:0/19:0/19:0), Trilinolein (TG 18:2/18:2/18:2), Triolein 
(TG 18:1/18:1/18:1), 1,2-Olein-3-Stearin (TG 18:1/18:1/18:0), 1,2-Stearin-3-Olein 
(TG 18:0/18:0/18:1), Triheptadecanoin (TG 17:0/17:0/17:0), and Tripalmitin 
(TG 16:0/16:0/16:0).  
Furthermore, FA and MG internal standards were purchased from Larodan. All other 
internal standards used for quantification, LPA, PA, LPC, PC, LPE, PE, PG, PS, Cer, 
HexCer, and SM were ordered from Avanti (Alabaster, Alabama, USA), while PI was 
obtained from Christoph Thiele.  
Water (aqua ad iniectabilia) for sample homogenization was purchased from B. Braun 
(Melsungen, Germany). Purified water was produced by Millipore Milli Q UF-Plus water 
purification system (Molsheim, France).  
 
2.2 Stock Solutions 
 
Lipid species were quantified by addition of non-endogenous internal standards. All 
diacylglycerol and triacylglycerol standards were dissolved in isooctane/isopropanol 
(3:1 v/v) at a concentration of 1.0 mg/mL. The internal standard (IS) solution contained 
trinonadecanoin, triheptadecanoin, and diarachidin each at a concentration of 
10 μg/mL in chloroform/methanol (9:1 v/v). In previous experiments the internal 
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standard mixture included monoacylglycerol and fatty acyl standards. Both lipid 
species were adjusted to a concentration of 1.0 mg/mL. Whereas free fatty acyls were 
dissolved in pure methanol, monoacylglycerols were dissolved in isooctane/2-propanol 
(1:1 v/v). In addition to DG and TG standards mentioned above, the standard solutions 
for the initial tests included also monotridecanoin, monononadecanoin, tridecanoic acid 
and tricosanoic acid each at a concentration of 10 μg/mL. Comparison of different 
solvents used in negative ion mode was performed by adding an internal cell standard, 
which is shown in Table 2.1. The spiked volume added to all samples during extraction 
was 50 μL.  
 
Table 2.1: Internal standard used for negative ion mode experiments. 
Species MW Cell IS 
Unit [g/mol] [ng/spike] [nmol/spike] 
PC 28:0 677.50 1250 1.845 
PC 44:0 901.75 1250 1.386 
LPC 13:0 453.29 50 0.110 
LPC 19:0 537.38 50 0.093 
PE 28:0 635.45 500 0.7868 
PE 40:0 803.64 500 0.6222 
LPE 13:0 411.24 50 0.1216 
PS 28:0 679.44 750 1.1038 
PS 40:0 847.63 750 0.8848 
PG 28:0 666.45 125 0.1876 
PG 40:0 834.63 125 0.1498 
PI 34:0 838.56 250 0.2981 
Cer 32:1;2 509.48 50 0.0981 
Cer 35:1;2 551.53 50 0.0907 
HexCer 30:1;2 643.50 60 0.0932 
HexCer 35:1;2 713.58 60 0.0841 
SM 30:1;2 646.50 500 0.7734 
TG 51:0 848.78 900 1.0603 
TG 57:0 932.88 900 0.9648 
DG 28:0 512.44 250 0.4879 
DG 40:0 680.63 250 0.3673 
MG 13:0 288.23 250 0.8674 
MG 19:0 372.32 250 0.6715 
FA 13:0 214.19 250 1.1672 
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2.3 Laboratory Equipment 
 
Table 2.2: Laboratory Equipment at the University Hospital Regensburg. 
Centrifuge Megafuge 1.0R Heraeus (Hanau, Germany) 
Eppendorf Tubes Eppendorf AG (Hamburg, Germany) 
Glass Centrifuge Tubes Hecht-Assistent (Sondheim, Germany) 
Feces catcher MED+ORG (Schwarzwald-Baar-Kreis, Germany) 
Filtration Milli-Q UF Plus Merck Millipore (Darmstadt, Germany) 
GCMS-QP2010 Shimadzu (Kyoto, Japan) 
GentleMACS Dissociator Miltenyi Biotec (Bergisch Gladbach, Germany 
GentleMACS 10 mL Tubes Miltenyi Biotec (Bergisch Gladbach, Germany 
PARAM Fecal analysis Tube Sarstedt AG & Co. KG (Nümbrecht, Germany) 
PAL autosampler CTC Analytics (Zwingen, Switzerland) 
Precellys homogenizer Bertin Instruments (Montigny-le-Bretonneux, 
France)  
Precellys lysing kit Bertin Instruments (Montigny-le-Bretonneux, 
France)  
Pyrex Culture Tubes SciLabware Ltd (Riverside, UK) 
Q Exactive Orbitrap Thermo Fisher Scientific (Bremen, Germany) 
Quattro Ultima MS Micromass Communications Inc (Manchester, 
UK) 
Sample Vials (1.5 mL volume) VWR (Darmstadt, Germany) 
Screw Caps (PTFE naturelle) VWR (Darmstadt, Germany) 
Screw Caps (PTFE, Sil, PTFE) VWR (Darmstadt, Germany) 
SpeedVac Christ (Osterode, Germany) 
Sarstedt 15 mL Tubes  Sarstedt AG & Co. KG (Nümbrecht, Germany) 
Thermomixer Eppendorf AG (Hamburg, Germany) 
Tecan Genesis RSP 150 Tecan Group Ltd (Männedorf, Switzerland) 
Ultimate 3000 isocratic pump Thermo Fisher Scientific (Waltham, MA, USA) 
Ultrasonic Desintegrator B.Braun Melsungen (Melsungen, Germany) 
Ultrasonic Bath Sonorex Bandelin (Berlin, Germany) 
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2.4 Samples  
 
Human fecal material was obtained from healthy volunteers for method development. 
Polypropylene tubes were used for sample collection. The material was gathered in 
the morning, immediately stored at -20°C and transported to the laboratory on ice. 
Samples were stored at -80°C until further processing. Samples used to investigate 
the influence of stool grade were collected as described by Kjølbæk et al. (159). This 
trial was registered under ClinicalTrials.gov Identifier no. NCT02215343.  
 
Human plasma samples were collected from residual patient material after clinical 
routine diagnostics.  
 
2.5 Sample Preparation 
 
2.5.1 Feces Homogenization 
 
A pea-sized, randomly selected part of the raw fecal material was homogenized in 
2.5 mL isopropanol/water (70/30, v/v) using a gentleMACSTM Dissociator (Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany) as described previously by Schött et al. 
(124). The homogenate was further diluted in 2.5 mL of 70% isopropanol and again 
homogenized. Homogenization was repeated twice. After vortexing briefly, 1.0 mL of 
this mixture was vacuum dried overnight to determine the dry weight (dw) of the raw 
fecal homogenate. The samples were diluted to a final concentration of 2.0 mg dry 
weight/mL (mg dw/mL) for further analysis. Samples were always kept on ice and 
stored at -80°C until further processing.  
To perform the pre-analytical tests the raw feces were first homogenized in 10.0 mL 
water (B. Braun). The homogenization was repeated twice and the samples were kept 
on ice between each preparation step. After homogenization 70% of an organic solvent 
(e.g. methanol, ethanol or isopropanol) or water was added to 30% homogenate in a 
15 mL Falcon tube. From this mixture, 1.0 mL each was divided into 1.5 mL Eppendorf 
tubes and stored under different conditions. The samples were kept either at room 
temperature (RT) or in the refrigerator at 4°C. Reference samples were immediately 
stored at -80°C. After defined times (1 h, 4 h, 24 h, and 4 days) the remaining samples 
were also stored at -80°C until further processing.  
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2.5.2 Lipid Extraction 
 
An amount of 50 μL of the internal standard solution (containing 0.54 nmol TG 57:0, 
0.59 nmol TG 51:0, and 0.73 nmol DG 40:0) was added to a sample volume of 100 μL 
(2 mg dw/mL) fecal homogenate in a glass centrifuge tube before lipid extraction. 
Extraction occured according to the protocol by Bligh and Dyer (121). An amount of 
700 μL H2O and 3.0 mL B&D solution (CHCl3/MeOH 1:2 v/v) were added to the sample 
material. The mixture was vortexed for 5 sec and incubated at room temperature for at 
least 60 min. Subsequently, 1.0 mL CHCl3 and 1.0 mL H2O were added. The mixture 
was vortexed for another 5 sec and centrifuged at 4000 rpm (17,860 g) for 10 min. A 
volume of 1200 μL of the separated chloroform phase was transferred into a 1.5 mL 
glass sample vial by a pipetting robot (Tecan Genesis RSP 150) and evaporated to 
dryness in a vacuum concentrator. The residues were dissolved in 1.0 mL 
chloroform/methanol/2-propanol (1:2:4 v/v/v) containing 7.5 mM ammonium formate.  
For the experiments measured in negative ion mode an internal standard solution (see 
Table 2.1) was added to a sample amount of 100 μL fecal homogenate or 10 μL 
plasma. The samples were extracted as described above. An amount of 300 μL of the 
separated chloroform phase was removed from all samples as mentioned earlier. The 
residues were dissolved in either 300 μL (feces) or 700 μL (plasma) 
chloroform/methanol/2-propanol (1:2:4 v/v/v) containing 7.5 mM ammonium formate 
and MeOH/CHCl3 (5:1 v/v) containing 0.005% methylamine, respectively.  
Experiments in negative ion mode involved also different solvents and methylamine 
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Table 2.3: Comparison of different solvents, additives, and concentrations for 
measurements in negative ion mode. Solvents containing methylamine were either 
prepared from aqueous (a) or EtOH-containing (b) solutions. Experiments using LM2 
(MeOH/CHCl3 (5:1 v/v)) were performed in different concentrations of methylamine 
solution.  
 
 Solvent Additive Concentration 



































ammonium formate 7.5 mM 









2.6 Flow Injection Fourier Transform Mass Spectrometry 
 
Mass spectrometric analysis of the reconstituted lipid extracts was performed by direct 
flow injection analysis using Fourier transform mass spectrometry (FIA-FTMS). A 
hybrid quadrupole Orbitrap mass spectrometer Q Exactive (Thermo Fisher Scientific, 
Bremen, Germany) equipped with a heated electrospray ionization source was coupled 
to a PAL autosampler (CTC Analytics, Zwingen, Switzerland) and an UltiMate 3000 
isocratic pump (Thermo Fisher Scientific, Waltham, MA, USA). The injection volume 
was 50 μL and a solvent mixture of chloroform/methanol/2-propanol (1:2:4 v/v/v) was 
delivered at an initial flow rate of 100 μL/min until 0.25 min, followed by 10 μL/min for 
2.5 min and a wash out with 300 μL/min for 0.5 min. The ion-source was operated in 
positive ion mode using the following parameters: spray voltage 3.5 kV, capillary 
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temperature of 281°C, S-lens RF level 55, aux gas heater temperature of 250°C and 
flow rates of 58 for sheath gas and 16 for aux gas. FTMS data were recorded in positive 
ion mode with a maximum injection time (IT) of 200 ms, an automated gain control 
(AGC) of 1∙106, three microscans and a target resolution of 140,000 (at m/z 200). 
Diacylglycerol was measured in a mass rage m/z 450 – 800 and triacylglycerol in a 
range of m/z 750 – 1200. MS2 spectra were acquired for 3 min in mass range 
m/z 450 – 1200 with a step size of 1.0008 Da and an isolation window of 1 Da with a 
normalized collision energy of 20%, an IT of 64 ms, AGC of 1∙105, and a target 
resolution of 17,500.  
In negative ion mode spray voltage was set to 2.5 kV. Data were acquired in three scan 
events. Free fatty acyls and monoacylglycerol were measured in a mass range 
m/z 150 - 450, lyso-glycerophospholipids and ceramides in a range of m/z 400 – 650, 
and glycerophospholipids in a range of m/z 520 – 960. The lower mass range was 
analyzed for 0.5 min (21 averaged scans), the middle mass range was analyzed for 





Fecal homogenates were documented using phase contrast microscopy with 10 x 
magnification (Zeiss Primovert, Jena, Germany) and the ZEN 2.6 lite imaging software.  
 
2.8 Lipid Identification and Data Processing 
 
ALEX software (160) was used for peak assignment and offset correction of data 
acquired by FTMS and MS/FTMS (MS2) using a m/z-tolerance of ± 0.0045 Da. Peaks 
with mass deviation of more than 3 ppm were not considered. ALEX software operates 
in several steps. In the first step, the output (.raw) files were converted into txt-files. 
Subsequently, the peak information in the txt-files was screened for possible lipids in 
a non-targeted approach. This step includes information about the isotope peaks. 
Emass was used for the calculation of accurate masses and probabilities of isotopic 
peaks as described earlier (161). Adapted to the International Union of Pure and 
Applied Chemistry atomic isotope probabilities were applied (162).  
The offset correction of the FTMS experiments was performed by averaging the mass 
deviation of internal standards in positive ion mode of DG 40:0, TG 51:0, and TG 57:0 
and in the negative ion mode of the lipid species listed in Table 2.4 for each mass 
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range, see 2.6 Flow Injection Fourier Transform Mass Spectrometry. A tolerance of 
∆m/z 0.01 was selected. Regardless of the selected m/z tolerance, the area for the 
assigned peaks was determined from baseline to baseline.  
 
Table 2.4: Internal standards used for offset correction in the ALEX software.  
 Species Adduct m/z 
positive ion mode DG 40:0 [M + NH4]+ 698.6657 
 TG 51:0 [M + NH4]+ 866.8171 
 TG 57:0 [M + NH4]+ 950.9110 
negative ion mode LPC 13:0 [M + HCOO]- 498.2837 
 PC 28:0 [M + HCOO]- 722.4978 
 LPE 13:0 [M - H]- 410.2313 
 PE 28:0 [M - H]- 634.4453 
 PI 34:0 [M - H]- 837.5499 
 PG 28:0 [M - H]- 665.4399 
 PS 28:0 [M - H]- 678.4352 
 Cer 32:1;2 [M + HCOO]- 554.4790 
 HexCer 30:1;2 [M + HCOO]- 688.5005 
 SM 30:1;2 [M + HCOO]- 691.5032 
 FA 13:0 [M - H]- 213.1860 
 MG 13:0 [M - H]- 287.2228 
 
Species assignment included evaluation of product ion spectra (see Figure 3.3). The 
assigned data were exported to Microsoft Excel 2010 and processed using self-
programmed macros. For accurate quantification intensities were corrected for Type I 
isotope effects (relative isotope abundance, (163)). Type II corrections (overlap mainly 
resulting from 13C-atoms) were not required at the selected mass resolution due to 
peak interference (Hoering et al. Manuscript in revision). The background correction 
was performed with an internal standard blank, dependent on the solvent used for 
feces homogenization (H2O or 2-propanol) analyzed within the same batch. The 
concentration of lipid species detected in the IS blanks were subtracted from the 
corresponding sample. Quantification was performed by normalization of analyte to 
internal standard intensities multiplied with the spiked amount of the internal standard 
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as described recently (164). Lipids were annotated as sum composition of acyl chains 
or without specification of sn-positions using “_” as previously proposed (89).  
 
2.9 Method Validation 
 
Method validation of FIA-FTMS included the determination of limit of quantifiaction 
(LoQ), intra-day and inter-day precision, linearity of quantification, and dilution integrity.  
 
LoQ of DG and TG species was determined from serial dilutions of different human 
fecal samples. Non-endogenous internal standard species DG 38:0, DG 36:6, 
DG 36:0, TG 54:2, TG 54:1 and TG 60:0 were analyzed in fivefold. The coefficient of 
variation (CV) and the absolute value of trueness – 100% were determined and plotted 
against the concentrations. The results were fitted by a power function. LoQ was 
calculated representing a CV of ≤ 20% and absolute value of trueness – 100% ≤ 20%, 
respectively. The higher concentration of both calculations was defined as LoQ. The 
concentrations of the titrated species are indicated in the corresponding figures (for 
details see 3.1.2 Limit of Quantification). 
 
Intra-day precision was assessed for five different human fecal samples which were 
extracted five times and quantified. For inter-day precision the experiment was 
repeated and the same samples were extracted and measured on five different days, 
within 20 days between first and last measurement.  
 
Linearity of quantification was determined using spiked samples of the synthetic 
standards DG 36:6, DG 38:0, TG 54:2, and TG 54:1 at six concentration levels. Each 
level was extracted in fivefold. The spiked concentration was plotted against the 
measured concentration and the results were fitted by a linear function. The experiment 
was performed using human fecal samples. The highest spike concentration was 
8.16 pmol/mg dw for DG 36:6, 7.66 pmol/mg dw for DG 38:0, 5.64 pmol/mg dw for 
TG 54:2, and 5.63 pmol/mg dw for TG 54:1. 
 
Dilution integrity of DG and TG species was determined by analysis of stool samples 
at different concentrations (from 1.6 mg dw/mL to 0.02 mg dw/mL). Samples were 
measured in triplicates. The measured quantity was compared to the target quantity 
determined at the highest sample concentration.  
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3. Results and Discussion 
 
3.1 Lipid Species Profile of Human Fecal Samples in Positive Ion Mode 
 
Our initial aim was to develop an accurate and fast method for the identification and 
quantification of lipid species in human fecal material using FIA-FTMS with a 
quadrupole Orbitrap hybrid mass spectrometer Q Exactive. Crude lipid extracts 
prepared by chloroform extraction according to the protocol by Bligh and Dyer (121) 
were analyzed in positive ion mode. Upon initial evaluation, spectra revealed a high 
heterogeneity (Figure 3.1) and numerous peaks could be assigned to [M+NH4]+ ions 
of DG and TG species. Other lipid classes were not detected in significant amounts. 
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Figure 3.1: Mass spectra of three individual human fecal samples analyzed in positive 
ion mode are displayed. Panel A shows the mass range of DG species (m/z 500 – 720) 
and panel B of TG species (m/z 810 - 980). The internal standards are indicated in 
blue. 
 
Quantification of lipid species was performed by adding internal standards to the 
sample before extraction. Ideally two lipid species which are not present in the sample 
material are used per lipid class. 
In a first step, 20 different fecal samples were screened for their DG and TG species. 
None of the analyzed samples contained signals representing a relevant interference 
with the selected internal standards (IS) DG 40:0, TG 51:0 and TG 57:0 (Figure 3.2). 
DG 28:0 which is typically used for DG quantification in plasma or tissue was 
detectable in some fecal samples and thus could not be used as internal standard.  
B 
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Figure 3.2: Mass spectra of four individual human fecal samples analyzed in positive 
ion mode are displayed. Panel A shows the mass range of DG 40:0 (m/z 698.6657), 
panel B of TG 51:0 (m/z 866.8171) and panel C of TG 57:0 (m/z 950.9110) for samples 
without (upper three spectra) and with internal standards (bottom spectrum). 
 
 
To prove the identity of detected species, MS2 spectra were evaluated and product 
ions were assigned according to the annotation system proposed recently (128) 
(exemplified in Figure 3.3).  
 
High resolution FTMS analysis detected ammoniated DG 34:2 at m/z 610.5405 
(2.8 ppm mass accuracy). MS2 analysis of m/z 610.5 detected a LCF at m/z 575.5042, 
corresponding to the neutral loss of H2O and ammonia, which is annotated as 
“-DG(35)”. The MLFs derived from DG 34:2 contained the fragments "-FA 16:0" at 
m/z 337.2736 and “-FA 18:2” at m/z 313.2736 derived from neutral losses. In addition, 
fragments specific to lipid species were observed for TG, for example, TG 52:4 at 
m/z 872.8, showed NL fragments: “-FA 16:0” at m/z 599.5028 and “-FA 18:2” at 
m/z 575.5040.  
In some cases, a strong sample dependence could be observed. Whereas DG 36:2, 
for example, consisted of two FA 18:1 in some samples, in others following 
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combination could be found: DG 18:0_18:2. Especially for TG it could be observed that 
several fatty acyl combinations occur in one sample. For example, TG 54:6 at 
m/z 896.8 revealed a NL of “-FA 18:0” at m/z 595.4703, “-FA 18:1” at m/z 597.4846, 
“-FA 18:2” at m/z 599.5009 and “-FA 18:3” at m/z 601.5158, with a mass accuracy 
better than 5.5 ppm. Thus different combinations were possible: TG 18:0_18:3_18:3, 
TG 18:1_18:2_18:3, and TG 18:2_18:2_18:2. Whereas “-FA 18:2” and “-FA 18:3” 
showed high intensities in the spectrum, these were significantly lower for “-FA 18:1” 
and “-FA 18:0”.  
The detected NL fragments comprised mainly acyl chains with 16 and 18 carbons and 
up to three double bonds. For DG, also species containing FA 12:0 and 14:0 were 
detected precluding application of DG 28:0 as IS. 
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DG 34:2  DG 16:0_18:2 
 
DG 36:4  DG 18:2_18:2 
 
DG 36:3  DG 18:1_18:2 
 
DG 36:2  DG 18:0_18:2 ; DG 18:1_18:1 
 
7 #505 RT: 1.93 AV: 1 NL: 1.48E5
T: FTMS + p ESI Full ms2 610.3680@hcd20.00 [50.0000-640.0000]





























263.2365 355.069395.085979.9579 223.1700 391.1206
4 #529 RT: 1.96 AV: 1 NL: 5.20E5
T: FTMS + p ESI Full ms2 634.3872@hcd20.00 [50.0000-665.0000]





























149.1322109.1014 175.1482 319.2632 351.2512 396.7650 543.4903220.3969
4 #531 RT: 1.97 AV: 1 NL: 1.87E5
T: FTMS + p ESI Full ms2 636.3888@hcd20.00 [50.0000-665.0000]






























245.2256 381.3002 417.2878 470.0348 508.7685
4 #533 RT: 1.97 AV: 1 NL: 1.47E5
T: FTMS + p ESI Full ms2 638.3904@hcd20.00 [50.0000-670.0000]




























265.2525 323.2581 381.2726 429.5704295.8164
--DG (35) 
-FA 16:0(-H) -DG(35) 
-FA 18:2(-H) -DG(35) 
--DG (35) 
-FA 18:2(-H) -DG(35) 
--DG (35) 
-FA 18:2(-H) -DG(35) -FA 18:1(-H) -DG( ) 
--DG (35) 
-FA 18:1(-H) -DG(35) 
-FA 18:0(-H) -DG(35) -FA 18:2(-H) -DG(35) 
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DG 30:0  DG 12:0_18:0 
 
TG 50:0  TG 16:0_16:0_18:0 
 
TG 52:4  TG 16:0_18:2_18:2 
 
TG 54:6  TG 18:0_18:3_18:3 ; TG 18:1_18:2_18:3 ; TG 18:2_18:2_18:2 
 
5 #453 RT: 1.84 AV: 1 NL: 1.96E4
T: FTMS + p ESI Full ms2 558.3264@hcd20.00 [50.0000-590.0000]






























584.1670559.3386151.5933 244.341371.9332 216.3720175.8727 489.4738105.5941
5 #747 RT: 2.34 AV: 1 NL: 1.82E4
T: FTMS + p ESI Full ms2 852.5616@hcd20.00 [59.3333-890.0000]






























10 #767 RT: 2.37 AV: 1 NL: 3.04E5
T: FTMS + p ESI Full ms2 872.5776@hcd20.00 [60.6667-910.0000]





























Am1 #791 RT: 2.41 AV: 1 NL: 7.49E5
T: FTMS + p ESI Full ms2 896.5968@hcd20.00 [62.3333-935.0000]

































-FA 12:0(-H) -DG(35) 
-FA 18:0(-H) -DG(35) 
-FA 16:0(+HO) -TG(17) 
-FA 18:0(+HO) -TG(17) 
-FA 18:2(+HO) -TG(17) 
-FA 16:0(+HO) -TG(17) 
-FA 18:3(+HO) -TG(17) 
-FA 18:2(+HO) -TG(17) 
-FA 18:1(+HO) -TG(17) 
-FA 18:0(+HO) -TG(17) 
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TG 54:5  TG 18:1_18:2_18:2 
 
TG 54:4  TG 18:1_18:1_18:2 
 
TG 54:3  TG 18:1_18:1_18:1 
 
 




The concentrations of DG and TG species detected in these samples span a range up 
to or more than three orders of magnitude (Table 3.1). Highest mean concentrations 
were detected for polyunsaturated species with more than two double bonds: DG 36:3, 
DG 36:4, TG 54:3, TG 54:4 and TG 54:5.  
10 #793 RT: 2.42 AV: 1 NL: 8.72E5
T: FTMS + p ESI Full ms2 898.5984@hcd20.00 [62.3333-935.0000]





























10 #795 RT: 2.42 AV: 1 NL: 1.02E6
T: FTMS + p ESI Full ms2 900.6000@hcd20.00 [62.3333-935.0000]




























10 #797 RT: 2.42 AV: 1 NL: 3.94E6
T: FTMS + p ESI Full ms2 902.6016@hcd20.00 [62.6667-940.0000]



























339.288795.0860 135.1170 902.7252177.2474 691.1254423.3565
-FA 18:2(+HO) -TG(17) 
-FA 18:1(+HO) -TG(17) 
-FA 18:2(+HO) -TG(17) 
-FA 18:1(+HO) -TG(17) 
-FA 18:1(+HO) -TG(17) 
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Table 3.1: Concentrations and acyl combinations of DG and TG species in human 
feces from 20 different samples. Data based on a single measurement of the individual 
samples and acyl combinations were derived from MS2 spectra. 
 
Compound 
[M+NH4]+ mean ± standard deviation 
[nmol/mg dw] 
median min max acyl combinations 
m/z 
DG 26:0 502.447 0.139 ± 0.348 0.004 n.d. 1.401 DG 12:0_14:0 
DG 28:0 530.478 0.08 ± 0.214 0.002 n.d. 0.919 DG 12:0_16:0 
 
   
 
   DG 14:0_14:0 
DG 30:0 558.509 0.106 ± 0.322 0.008 n.d. 1.454 DG 12:0_18:0 
 
   
 
   DG 14:0_16:0 
DG 34:3 608.525 0.428 ± 0.66 0.24 n.d. 2.808 DG 16:0_18:3 
DG 34:2 610.541 1.865 ± 1.856 0.994 0.045 6.198 DG 16:0_18:2 
DG 34:1 612.556 0.776 ± 0.711 0.503 0.068 2.417 DG 16:0_18:1 
DG 36:5 632.525 1.254 ± 1.922 0.726 0.002 8.481 DG 18:2_18:3 
DG 36:4 634.541 7.305 ± 8.349 4.302 0.053 32.355 DG 18:2_18:2 
 
   
 
   DG 18:1_18:3 
DG 36:3 636.556 4.371 ± 4.513 2.452 0.042 14.508 DG 18:1_18:2 
DG 36:2 638.572 3.632 ± 4.283 2.564 0.074 17.947 DG 18:1_18:1 
 
   
 
   DG 18:0_18:2 
TG 48:0 824.77 0.042 ± 0.104 0.01 n.d. 0.491 TG 16:0_16:0_16:0 
TG 50:3 846.755 0.475 ± 0.465 0.445 0.018 1.008 TG 16:0_16:1_18:2 





    TG 16:0_16:1_18:1 
TG 50:1 850.786 0.083 ± 0.116 0.032 0.006 0.43 TG 16:0_16:0_18:1 
TG 50:0 852.801 0.164 ± 0.466 0.031 n.d. 2.088 TG 16:0_16:0_18:0 





    TG 16:0_18:2_18:3 





    TG 16:1_18:1_18:1 
TG 52:3 874.786 0.487 ± 0.901 0.174 n.d. 3.666 TG 16:0_18:1_18:2 





    TG 16:0_18:0_18:2 
TG 53:4 886.786 0.269 ± 0.27 0.234 0.005 0.624 TG 17:1_18:1_18:2 
TG 54:9 890.723 0.078 ± 0.16 0.003 n.d. 0.641 TG 18:3_18:3_18:3 
TG 54:7 894.755 0.409 ± 0.528 0.08 n.d. 1.895 TG 18:2_18:2_18:3 












    TG 18:2_18:2_18:2 
TG 54:5 898.786 1.174 ± 1.886 0.599 0.003 7.875 TG 18:1_18:2_18:2 





    TG 18:0_18:1_18:3 
TG 54:3 902.817 1.523 ± 3.239 0.294 0.008 11.56 TG 18:1_18:1_18:1 
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3.1.1 Reproducibility 
 
In an important next step within method development (165, 166) we evaluated the 
performance of the FIA-FTMS method. Due to sample heterogeneity intra- and inter-
day precisions were evaluated in five different samples (Table 3.2 and Table 3.3). The 
coefficients of variation (CV) were below 15% or even below 10% for most DG species. 
For sample 5 significantly higher variations were observed especially for TG species 
concentrations (see also 3.1.4 Evaluation of Reproducibility Issues). Moreover, we 
observed a decrease in the concentrations of most of the TG species from day to day. 
Despite storage of the samples in 70% isopropanol at -80°C, this decline may be 
related to lipase activity since enzymatic activity has also been reported in organic 
solvents (167, 168).  
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Table 3.2: Coefficient of variation (CV) of intra- and interday precision of DG species 




  Intraday 
CV [%] 
Interday 
CV [%] sample Mean (n=5) Mean (n=5) 
  [nmol/ mg dw] [nmol/ mg dw] 
DG 34:3 sample 1 0.13 7.2 0.13 11.6 
 sample 2 0.36 16 0.38 13.7 
 sample 3 0.61 6.4 0.63 8.1 
 sample 4 0.59 3.7 0.53 4.3 




   
DG 34:2 sample 1 1.45 2.7 1.48 6.4 
 sample 2 3.37 16.2 3.53 13.4 
 sample 3 4.32 6.3 4.43 7 
 sample 4 7.55 1.6 4.79 4.5 




   
DG 34:1 sample 1 1.87 3.6 1.92 7.2 
 sample 2 0.67 15.1 0.69 14.8 
 sample 3 1.85 7.2 1.89 7.7 
 sample 4 5.66 1.9 5.16 2.1 




   
DG 36:5 sample 1 0.29 6.6 0.29 10.3 
 sample 2 1.09 16.4 1.14 13.2 
 sample 3 1.69 5.7 1.74 8.2 
 sample 4 n.d. 
 n.d.  
 sample 5 0.4 4.5 0.38 7.2 
  
 
   
DG 36:4 sample 1 4.32 3.2 4.38 7.5 
 sample 2 10.99 16.2 11.5 13.2 
 sample 3 14.31 6.3 14.68 7.3 
 sample 4 13.2 2.3 11.92 4 
 sample 5 5.95 9.6 5.9 9.3 
  
 
   
DG 36:3 sample 1 5.89 2.3 5.98 6.1 
 sample 2 5.82 14 6.04 11.6 
 sample 3 11.29 6.9 11.61 8.1 
 sample 4 43.5 2 39.27 3.9 
 sample 5 2.89 4.6 2.75 5.6 
  
 
   
DG 36:2 sample 1 10.27 2.2 10.43 6.2 
 sample 2 2.38 14.4 2.48 11.7 
 sample 3 6.5 7.7 6.65 7.9 
 sample 4 53.49 2.2 48.53 3.2 
  sample 5 1.9 3.2 1.83 5.5 
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Table 3.3: Coefficient of variation (CV) of intra- and interday precision of TG species 







CV [%] sample Mean (n=5) Mean (n=5) 
 [nmol/ mg dw] [nmol/ mg dw] 
TG 50:2 sample 1 n.d.  n.d.  
 sample 2 0.13 10.5 0.14 15.7 
 sample 3 4.15 7.1 4.15 7.4 
 sample 4 3.5 10.4 3.17 9.9 
 sample 5 0.19 97.3 0.11 118.3 
      
TG 50:1 sample 1 0.17 1.9 0.18 12.1 
 sample 2 n.d.  n.d.  
 sample 3 1.26 5.8 1.26 5.9 
 sample 4 1.01 10.5 0.92 9.9 
 sample 5 n.d. 
 n.d.  
      
TG 50:0 sample 1 0.22 10.5 0.24 20.1 
 sample 2 n.d.  n.d.  
 sample 3 n.d.  n.d.  
 sample 4 n.d.  n.d.  
 sample 5 0.1 7.4 0.1 9.9 
      
TG 52:5 sample 1 n.d.  n.d.  
 sample 2 0.11 7.3 0.11 10.7 
 sample 3 3.41 7.8 3.49 11.9 
 sample 4 2.1 8.9 1.91 8.5 
 sample 5 n.d. 
 n.d.  
      
TG 52:4 sample 1 0.32 5.9 0.32 14.2 
 sample 2 0.82 7.6 0.84 11.6 
 sample 3 27.9 6.9 27.76 7.8 
 sample 4 20.26 9.4 18.36 9 
 sample 5 1.25 87.4 0.66 116.8 
      
TG 52:3 sample 1 0.39 9 0.41 16.2 
 sample 2 0.44 13.5 0.46 13.4 
 sample 3 18.36 5.1 18.3 5.9 
 sample 4 65.61 10.4 59.35 10.1 
 sample 5 0.35 23.6 0.37 140.5 
      
TG 52:2 sample 1 1.04 11.1 1.09 14.8 
 sample 2 0.21 10.5 0.22 13.5 
 sample 3 9.74 4.9 9.77 6 
 sample 4 45.75 10.8 41.29 10.5 
 sample 5 0.35 92.8 0.18 129.3 
      
TG 54:7 sample 1 n.d.  n.d.  
 sample 2 0.24 7.1 0.24 9.8 
 sample 3 14.67 8.6 15.1 14.7 
 sample 4 0.21 13.9 0.19 13.4 
  sample 5 n.d.  n.d.  
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Triacylglycerol 
  Intraday 
CV [%] 
Interday 
CV [%] sample Mean (n=5) Mean (n=5) 
  [nmol/ mg dw] [nmol/ mg dw] 
TG 54:6 sample 1 0.35 6 0.38 28.8 
 sample 2 1.24 9.7 1.27 11 
 sample 3 51.78 5.6 51.45 6.7 
 sample 4 20.86 9.2 18.89 8.9 
 sample 5 1.4 74.4 0.77 104.8 
 
     
TG 54:5 sample 1 0.82 9.5 0.85 18.9 
 sample 2 1.41 10.9 1.45 10.9 
 sample 3 52.48 4.1 52.47 5.6 
 sample 4 106.95 10.4 96.83 10 
 sample 5 1.85 102.5 0.92 146 
      
TG 54:4 sample 1 1.83 11.6 1.89 15.3 
 sample 2 0.93 11 0.96 11.6 
 sample 3 37.41 4.1 37.39 5.7 
 sample 4 175.39 10.5 146.61 26.1 
 sample 5 0.65 28.9 0.66 147.5 
      
TG 54:3 sample 1 4.78 11.3 4.91 14.2 
 sample 2 0.44 12 0.46 12.8 
 sample 3 18.69 4.2 18.72 5.8 
 sample 4 248.23 12.4 225.33 11.5 
  sample 5 0.6 88.8 0.29 131 
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3.1.2 Limit of Quantification 
 
Higher CV values were most likely related to concentrations close to limit of detection. 
Therefore, limit of quantification (LoQ) was determined functionally as described 
previously (124, 169). The LoQ was defined as concentration at which either the CV 
reached 20% or accuracy left the range of 80-120%. Non-endogenous DG and TG 
species were spiked at various concentrations and analyzed in fivefold. CV and 
accuracy were fitted as shown in Figure 3.4. The calculated LoQs were in the range of 
0.01-0.2 nmol/mg dw for DG species and 0.01-0.3 nmol/mg dw for TG species. LoQs 
determined at CV of 20% were significantly lower compared to those determined by 
accuracy. Most of the LoQs derived from CVs were in the range of 0.01 to 
0.02 nmol/mg dw which also matched the inter- and intra-day CVs listed in Table 3.2 
and Table 3.3. This demonstrates a reproducible analysis below 0.1 nmol/mg dw. 
LoQs derived from accuracy analysis depend on accurate addition of low amounts of 
DG/TG species, which may be compromised by different factors including analyte 
absorption or inhomogeneity issues (see 3.1.4 Evaluation of Reproducibility Issues). 
Except a poor curve fit as a factor, we could not find an explanation for the order of 
magnitude difference between the LoQs determined for different species. There seems 
to be neither a relation to species chain length nor to number of double bonds. LoQs 
for DG and TG appear to be similar. Based on these considerations, we applied 
0.02 nmol/mg dw as LoD and 0.1 nmol/mg dw as LoQ for practical reasons (this is also 
substantiated by data from dilution integrity testing shown under 3.1.3 Recovery, 
Linearity and Dilution Integrity).  
Validation of this method demonstrated its suitability for large scale studies including 
extraction, FIA-FTMS analysis, and data evaluation despite the higher variations 
observed for some samples. 
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Figure 3.4: Calculation of LoQ for DG 38:0, DG 36:6, DG 36:0, TG 54:2, TG 54:1 and 
TG 60:0 from serial dilutions of different human fecal samples each analyzed in 
fivefold. Left panels illustrate the measured CVs plotted against the concentration of 
undiluted samples, respectively. Right panels show the absolute values of trueness-
100 plotted against the concentration of undiluted samples, respectively. The results 
were fitted by a power function and concentrations were calculated at CV = 20% or at 
absolute values of trueness-100 = 20%. 
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3.1.3 Recovery, Linearity and Dilution Integrity 
 
Recovery of DG and TG species was determined at two spike levels (Table 3.4). Most 
of the determined recoveries were within the expected range of 85 to 115%. However, 
considering the high complexity of fecal material as matrix, we think that recoveries 
between 75% and 135% are acceptable.  
 
Table 3.4: Recovery data of DG and TG species in human feces. Concentrations were 













unspiked  n.d. ± n.d.  
Spike low 3.27 4.33 ± 0.21 132.6 
Spike high 16.3 17.3 ± 0.95 105.9 
 
      
DG 36:4 
unspiked  0.99 ± n.d.  
Spike low 3.24 3.93 ± 0.13 121.1 
Spike high 16.2 16.2 ± 0.86 99.8 
 
      
DG 36:0 
unspiked  n.d. ± n.d.  
Spike low 3.20 2.72 ± 0.09 84.8 
Spike high 16.0 12.1 ± 0.42 75.3 
 
      
DG 38:0 
unspiked  n.d. ± n.d.  
Spike low 3.07 3.13 ± n.d. 102.0 
Spike high 15.3 14.8 ± 0.47 96.8 
 
      
TG 48:0 
unspiked  0.13 ± n.d.  
Spike low 2.48 2.04 ± 0.12 82.1 
Spike high 12.4 10.4 ± 0.44 84.3 
 
      
TG 54:6 
unspiked  n.d. ± n.d.  
Spike low 2.28 2.52 ± 0.10 110.9 
Spike high 11.4 12.7 ± 0.89 111.6 
       
TG 54:3 
unspiked  n.d. ± n.d.  
Spike low 2.26 2.04 ± n.d. 90.2 
Spike high 11.3 10.2 ± 0.65 90.5 
 
      
TG 54:1 
unspiked  n.d. ± n.d.  
Spike low 2.25 2.32 ± n.d. 103.3 
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A major goal of high-resolution shotgun lipidomics approaches is an accurate 
quantification of lipid species. To further evaluate the dynamic range of the method the 
linearity of quantification was tested for several species not present in fecal samples. 
DG 36:6, DG 38:0, TG 54:2, and TG 54:1 were spiked at six different concentrations 
(Figure 3.5). All species revealed a good correlation of spiked and detected 
concentrations. A linear increase was observed with similar slopes for pure standards 
and matrix containing samples, which excludes significant effects of the matrix. 
However, species response seems to depend on structural features, as described for 
cholesteryl ester (164), and should be examined in detail in further studies. A linear 
range covering most of the tested samples was demonstrated up to 120 mg dw/mL 
and 90 mg dw/mL for DG and TG, respectively.  
 
Moreover, dilution integrity was tested by quantification of gradually diluted stool 
samples (1.6 mg dw/mL to 0.02 mg dw/mL). Low (DG 32:0, TG 48:0), medium 
(DG 34:2, TG 52:2) and high (DG 36:3, TG 54:4) abundant species showed good 
correlation of expected and measured concentrations (Figure 3.6). The assay was 
linear at low (DG 32:0 and TG 48:0) and high concentrations (DG 36:3, TG 54:4) and 
matched the above described LoQ and LoD and linear range (up to 250 mg DG dw/mL 
and 150 mg TG dw/mL), respectively.  
The concentration range of each synthetic standard tested lies within the concentration 
range of the fecal samples. Based on this result, we conclude that the FIA-FTMS 
method using shotgun lipidomics is applicable for quantitative analysis of fecal lipids.  
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Figure 3.5: Linearity of DG and TG standards. Means (n=5) of the measured were 
plotted against the spiked concentrations. 
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Figure 3.6: Dilution integrity of DG and TG species with low, medium, and high 
concentrations, respectively. Samples were analyzed in triplicates. The mean 
measured concentrations were plotted against the target concentrations. 
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3.1.4 Evaluation of Reproducibility Issues 
 
As described above, very high variations were observed for some samples (about 10% 
of tested fecal samples). Therefore, various experiments were performed to evaluate 
the origin of irreproducibility. Despite thorough mechanical homogenization fecal 
samples are suspensions and a lack of homogeneity may cause variations. 
 
3.1.4.1 Effect of Centrifugation 
 
First, we tested whether centrifugation affected DG and TG concentrations. Five 
samples showing high variations were analyzed without centrifugation as well as after 
centrifugation (Table 3.5 and Table 3.6).  
 
Table 3.5: Five different samples were analyzed without centrifugation as well as their 
supernatant and pellet after centrifugation. Each sample was analyzed in triplicates. 










DG 34:3 sample 1 0.19 46.5 53.5 
 sample 2 0.13 53.0 47.0 
 sample 3 n.d. 53.1 46.9 
 sample 4 0.13 57.9 42.1 
 sample 5 0.06 41.7 58.3 
     
DG 34:2 sample 1 2.97 47.9 52.1 
 sample 2 1.62 48.3 51.7 
 sample 3 0.56 46.4 53.6 
 sample 4 1.15 53.4 46.6 
 sample 5 1.16 44.2 55.8 
     
DG 34:1 sample 1 0.78 48.0 52.0 
 sample 2 6.73 48.3 51.7 
 sample 3 2.07 45.6 54.4 
 sample 4 1.48 53.4 46.6 
 sample 5 0.20 46.6 53.4 
     
DG 36:5 sample 1 0.20 47.8 52.2 
 sample 2 0.10 50.3 49.7 
 sample 3 n.d. 59.7 40.3 
 sample 4 0.24 55.0 45.0 
 sample 5 0.25 45.2 54.8 
     
DG 36:4 sample 1 13.35 47.9 52.1 
 sample 2 3.15 50.0 50.0 
 sample 3 1.19 51.4 48.6 
 sample 4 3.66 55.4 44.6 
 sample 5 3.81 45.1 54.9 
     
DG 36:3 sample 1 5.85 48.1 51.9 
 sample 2 12.21 48.5 51.5 
 sample 3 3.42 47.2 52.8 
 sample 4 4.43 53.8 46.2 
 sample 5 1.88 45.6 54.4 
     
DG 36:2 sample 1 2.79 47.6 52.4 
 sample 2 47.41 48.0 52.0 
 sample 3 13.67 45.7 54.3 
 sample 4 7.25 53.1 46.9 
 sample 5 1.25 46.1 53.9 
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Table 3.6: Five different samples were analyzed without centrifugation as well as their 
supernatant and pellet after centrifugation. Each sample was analyzed in triplicates. 
Mean TG species concentrations and the fraction found in supernatant and pellet are 
displayed.  
 







TG 52:4 sample 1 0.26 47.8 52.2 
 sample 2 0.24 22.0 78.0 
 sample 3 0.18 20.7 79.3 
 sample 4 0.13 44.0 56.0 
 sample 5 0.13 11.2 88.8 
 
    
TG 52:3 sample 1 n.d. 45.8 54.2 
 sample 2 0.75 27.1 72.9 
 sample 3 0.73 11.7 88.3 
 sample 4 0.22 38.4 61.6 
 sample 5 n.d. 8.3 91.7 
 
    
TG 52:2 sample 1 n.d. 40.5 59.5 
 sample 2 2.65 25.7 74.3 
 sample 3 2.68 9.7 90.3 
 sample 4 0.63 37.2 62.8 
 sample 5 n.d. 8.4 91.6 
 
    
TG 54:7 sample 1 n.d. 44.1 55.9 
 sample 2 n.d. 17.2 82.8 
 sample 3 n.d. 15.4 84.6 
 sample 4 n.d. 48.2 51.8 
 sample 5 n.d. 11.8 88.2 
 
    
TG 54:6 sample 1 0.46 47.8 52.2 
 sample 2 0.39 17.1 82.9 
 sample 3 0.21 21.9 78.1 
 sample 4 0.17 44.3 55.7 
 sample 5 0.15 8.7 91.3 
 
    
TG 54:5 sample 1 0.31 47.8 52.2 
 sample 2 1.12 30.2 69.8 
 sample 3 0.92 14.2 85.8 
 sample 4 0.42 38.7 61.3 
 sample 5 n.d. 9.1 90.9 
 
    
TG 54:4 sample 1 0.20 47.3 52.7 
 sample 2 4.29 27.7 72.3 
 sample 3 3.73 10.6 89.4 
 sample 4 1.06 35.7 64.3 
 sample 5 n.d. 9.1 90.9 
 
    
TG 54:3 sample 1 n.d. 47.6 52.4 
 sample 2 14.66 27.5 72.5 
 sample 3 13.59 8.7 91.3 
 sample 4 2.99 38.2 61.8 
  sample 5 n.d. 12.3 87.7 
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Whereas DG species were detected in both pellet and supernatant, TG species were 
found in three of the samples enriched in the pellet (Figure 3.7). However, the DG/TG 
species profiles of supernatant and pellet closely resembled each other (Table 3.7 and 
Table 3.8), suggesting that centrifugation does not separate a specific pool of these 
lipid classes. However, due to the substantial amount of DG and TG in sample pellets, 




Figure 3.7: Five different samples were analyzed without centrifugation as well as their 
supernatant and pellet after centrifugation. Each sample was analyzed in triplicates. 
Fractions found of either DG or TG species in supernatant and pellet are displayed, 
respectively. The panels show the values of only one sample which is characteristic 










Table 3.7: Species profile in % total DG of the data listed in Table 3.5. 
 
Species 




supernatant       
[%] 





supernatant         
[%] 





supernatant         
[%] 





supernatant         
[%] 





supernatant         
[%] 
 pellet          
[%] 
DG 34:3 0.7 0.4 0.5 0.2 0.2 0.1 0.3 0.3 0.2 0.7 0.6 0.5 0.7 0.6 0.7 
DG 34:2 11.2 11.5 11.6 2.2 2.2 2.2 2.5 2.6 2.6 5.9 6.0 6.0 12.7 12.5 13.1 
DG 34:1 2.9 2.0 2.0 9.1 9.2 9.2 9.3 9.3 9.5 7.6 7.3 7.5 2.2 2.2 2.1 
DG 36:5 0.7 0.6 0.6 0.1 0.1 0.1 0.2 0.2 0.1 1.2 1.2 1.1 2.7 2.7 2.7 
DG 36:4 50.1 49.0 49.6 4.3 4.2 3.9 5.4 5.3 4.3 18.8 18.3 17.2 41.5 41.5 42.0 
DG 36:3 22.0 23.2 23.3 16.6 16.6 16.4 15.5 16.0 15.4 22.8 22.9 23.0 20.5 20.2 20.1 
DG 36:2 10.5 10.7 11.0 64.4 64.6 65.0 61.8 61.5 62.8 37.3 38.1 39.2 13.7 13.8 13.5 
 
 
Table 3.8: Species profile in % total TG of the data listed in Table 3.6. 
 
Species 




supernatant         
[%] 





supernatant         
[%] 





supernatant         
[%] 





supernatant         
[%] 





supernatant         
[%] 
 pellet          
[%] 
TG 52:4 18.0 19.3 19.0 1.0 1.0 1.3 0.8 1.6 0.7 2.3 3.0 2.4 24.0 24.5 20.4 
TG 52:3 5.7 5.3 5.7 3.1 3.2 3.2 3.3 3.8 3.0 4.0 4.3 4.2 6.9 7.0 8.1 
TG 52:2 3.0 2.3 3.0 11.0 10.7 11.5 12.2 12.0 11.9 11.2 11.4 11.8 4.0 3.1 3.6 
TG 54:7 0.9 0.9 1.0 0.1 0.1 0.1 0.0 0.1 0.0 0.3 0.4 0.3 3.8 3.9 3.1 
TG 54:6 31.7 32.3 31.7 1.6 1.5 2.8 0.9 1.7 0.7 3.0 3.7 2.8 28.1 26.9 29.7 
TG 54:5 21.8 21.6 21.2 4.7 4.9 4.2 4.2 5.5 3.5 7.5 8.3 8.1 17.2 17.8 18.9 
TG 54:4 14.1 13.8 13.8 17.8 18.2 17.6 16.9 18.1 16.3 18.7 17.9 19.8 10.9 11.3 12.0 
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3.1.4.2 Effect of Bead Beating 
 
In order to improve the homogeneity of the fecal samples, a number of different 
experiments were carried out. After homogenization using the gentleMACSTM 
dissociator (as described under 2.5.1 Feces Homogenization) different samples were 
tested with an additional homogenization step using the Precellys® homogenizer (data 
shown in Table 3.9 and Table 3.10). For this experiment, a sample showing high 
variation in preliminary tests was homogenized again and then divided into four 
different Precellys ® tubes and measured in fivefold.  
 
Table 3.9: One sample was divided into four tubes and analyzed either with or without 
Precellys® after homogenization. Each sample was analyzed in fivefold. Mean DG 
species concentrations and the coefficient of variation (CV) are displayed. 
 
    without Precellys® Precellys® 
Diacylglycerol sample 
Mean (n=5)  
[nmol/mg dw] 
CV [%] 
Mean (n=5)  
[nmol/mg dw] 
CV [%] 
DG 34:2 sample I 0.48 12.9 0.51 7.8 
 sample II   0.53 11.3 
 sample III   0.48 8.0 
 sample IV   0.53 7.8 
DG 34:1 sample I 0.19 9.8 0.17 6.1 
 sample II   0.22 9.9 
 sample III   0.19 9.4 
 sample IV   0.19 8.8 
DG 36:4 sample I 2.30 7.1 2.46 5.2 
 sample II   2.49 10.9 
 sample III   2.30 5.7 
 sample IV   2.50 8.4 
DG 36:3 sample I 2.02 11.2 2.17 8.5 
 sample II   2.30 11.8 
 sample III   2.16 5.3 
 sample IV   2.31 8.0 
DG 36:2 sample I 0.69 9.6 0.73 5.9 
 sample II   0.80 10.4 
 sample III   0.73 7.7 
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Table 3.10: One sample was divided into four tubes and analyzed either with or without 
Precellys® after homogenization. Each sample was analyzed in fivefold. Mean TG 
species concentrations and the coefficient of variation (CV) are displayed. 
 






[nmol/mg dw] [nmol/mg dw] 
TG 50:2 sample I 0.34 16.3 0.26 10.4 
 sample II   0.3 11.4 
 sample III   0.24 10.5 
 sample IV   0.27 9.7 
TG 52:4 sample I 3.37 14 2.76 9.9 
 sample II   3.06 11.6 
 sample III   2.61 11.3 
 sample IV   2.81 10.9 
TG 52:3 sample I 2.19 12.2 1.74 12.2 
 sample II   1.84 12.2 
 sample III   1.64 9.7 
 sample IV   1.64 11.9 
TG 52:2 sample I 0.79 15.2 0.58 13 
 sample II   0.7 11.2 
 sample III   0.56 8.9 
 sample IV   0.59 6.4 
TG 54:6 sample I 9.69 8.2 8.06 9 
 sample II   8.86 13 
 sample III   7.79 11.1 
 sample IV   7.83 13.6 
TG 54:5 sample I 12.62 5.9 10.64 9.4 
 sample II   11.64 13.6 
 sample III   10.24 10.5 
 sample IV   10.21 12.9 
TG 54:4 sample I 6.39 8.6 5.25 11.5 
 sample II   5.9 13.2 
 sample III   4.99 9.2 
 sample IV   5.14 9.5 
TG 54:3 sample I 2.25 8.3 1.85 13.3 
 sample II   2.04 13 
 sample III   1.74 8.3 
  sample IV   1.76 10.3 
 
 
Samples showed CVs < 17% for all DG and TG species. Whereas CVs for TG 
decreased, similar CVs were observed for DG species. In summary, bead-beating did 
not result in significantly higher reproducibility.  
Furthermore, a decrease of TG species was observed which may be related to 
adsorption to the beads or lipolysis during this homogenization step. 
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3.1.4.3 Effect of Sample Concentration and Volume 
 
In a next step, we asked whether the amount of fecal material used for homogenization 
could improve reproducibility. Therefore, two approaches were followed. In the first 
step, fecal homogenates were adjusted to different concentrations: 0.5 mg dw/mL, 
1.0 mg dw/mL, and 2.0 mg dw/mL. An amount corresponding to 200 µg dry weight, i.e. 
100 µL, 200 µL, or 400 µL was used for extraction, thus sample amount was equal in 
all cases. For this experiment, two different raw fecal samples were homogenized and 
analyzed in fivefold. The data are shown in Table 3.11 and Table 3.12. Samples with 
a lower concentration and higher sample volume did not exhibit lower CVs. On the 
contrary, the CVs of triacylglycerol species were significantly higher (CV > 15%) in 
some cases compared to 2.0 mg dw/mL, with up to 52% for sample 1 and a dry weight 
of 0.5 mg dw/mL (TG 54:6).  
Both samples showed an increase in concentration of TG species using a higher 
sample concentration which could be related to particle aggregation at higher sample 
concentration. Aggregates (containing high amounts of TG) may result in an increased 











Table 3.11: Different sample concentrations (0.5 mg dw/mL, 1.0 mg dw/mL, and 2.0 mg dw/mL) of raw human fecal material were used 
for analysis of two different samples. An amount of either 100 µL, 200 µL or 400 µL was used for extraction. Each sample was analyzed 
in fivefold. Mean DG species concentrations and the coefficient of variation (CV) are displayed. 
 
Sample concentration 











DG 34:3 sample I 0.20 13.0 0.20 6.9 0.20 8.7 
 sample II 0.42 2.0 0.60 9.5 0.42 8.3 
DG 34:2 sample I 3.63 2.3 3.59 7.0 3.65 7.9 
 sample II 5.04 2.6 7.35 9.9 5.42 8.1 
DG 34:1 sample I 1.87 6.4 1.88 7.2 1.92 10.2 
 sample II 3.87 5.8 5.52 10.1 4.39 7.3 
DG 36:5 sample I 0.48 7.1 0.48 6.0 0.46 7.4 
 sample II n.d.  n.d.  n.d.  
DG 36:4 sample I 10.77 6.0 10.82 7.0 10.70 7.4 
 sample II 9.03 2.5 13.33 10.3 9.64 7.2 
DG 36:3 sample I 10.03 6.0 10.08 6.0 10.12 7.6 
 sample II 29.81 3.6 43.55 10.5 31.88 6.3 
DG 36:2 sample I 5.38 5.2 5.44 7.01 5.62 9.6 





































































Table 3.12: Different sample concentrations (0.5 mg dw/mL, 1.0 mg dw/mL, and 2.0 mg dw/mL) of raw human fecal material were used 
for analysis of two different samples. An amount of either 100 µL, 200 µL or 400 µL was used for extraction. Each sample was analyzed 
in fivefold. Mean TG species concentrations and the coefficient of variation (CV) are displayed. 
 
Sample concentration 
    0.5 mg dw/mL 1.0 mg dw/mL 2.0 mg dw/mL 
Triacylglycerol sample 
Mean (n=5)  
[nmol/mg dw] 
CV [%] 
Mean (n=5)  
[nmol/mg dw] 
CV [%] 
Mean (n=5)  
[nmol/mg dw] 
CV [%] 
TG 50:2 sample I n.d.  n.d.  n.d.  
 sample II 1.54 9.4 2.13 11.7 2.61 7.8 
TG 50:1 sample I n.d.  n.d.  n.d.  
 sample II 0.45 9.5 0.59 11.8 0.73 9.9 
TG 52:5 sample I n.d.  n.d.  n.d.  
 sample II 0.87 7.5 1.21 11.9 1.47 7.5 
TG 52:4 sample I 0.43 49.6 0.36 17.3 0.52 6.0 
 sample II 9.03 9.2 12.51 10.0 15.38 8.8 
TG 52:3 sample I 0.27 27.8 0.33 35.3 0.46 2.2 
 sample II 29.28 9.6 39.88 9.8 47.99 7.8 
TG 52:2 sample I 0.18 33.8 0.20 42.2 0.27 7.0 
 sample II 20.65 9.6 27.55 10.0 32.99 7.4 
TG 54:6 sample I 0.49 51.8 0.47 23.8 0.70 13.6 
 sample II 9.14 9.2 12.68 9.6 15.55 9.0 
TG 54:5 sample I 0.62 49.8 0.69 35.3 0.97 6.1 
 sample II 48.01 8.9 66.36 9.8 80.12 8.0 
TG 54:4 sample I 0.56 47.8 0.69 45.5 0.92 6.4 
 sample II 81.43 9.8 111.71 9.9 135.24 8.6 
TG 54:3 sample I 0.36 43.3 0.50 6.9 0.67 24.3 
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In the second approach, different volumes (100 µL and 400 µL) of the homogenized 
fecal samples were subjected to lipid extraction (Table 3.13 and Table 3.14). Mass 
spectrometric analysis was performed at the same concentration. In this experiment 
samples with 2.0 mg dw/mL from the previous tests were used. The application of 
higher sample volumes showed some decrease of CV, especially for TG species and 
samples with a high fraction of TG in the pellet. Considering that variation is mainly 
due to sample inhomogeneity, using a higher sample volume could explain lower 
variations.  
 
Table 3.13: Two different volumes of homogenized fecal material (2.0 mg dw/mL) were 
used for analysis of two different samples. Each sample was analyzed in fivefold. Mean 
DG species concentrations and the coefficient of variation (CV) are displayed. 
 
Volume 








DG 34:3 sample I 0.18 6.8 0.20 6.7 
 sample II 0.43 5.8 0.41 2.8 
DG 34:2 sample I 3.34 6.3 3.49 3.8 
 sample II 5.50 3.5 5.25 3.4 
DG 34:1 sample I 1.83 6.5 1.79 4.3 
 sample II 4.32 4.8 4.19 1.3 
DG 36:5 sample I 0.42 5.7 0.42 5.6 
 sample II n.d.  n.d.  
DG 36:4 sample I 9.63 5.4 10.04 5.2 
 sample II 9.89 4.1 9.24 4.9 
DG 36:3 sample I 9.33 9.5 9.56 4.6 
 sample II 33.06 4.3 30.84 4.3 
DG 36:2 sample I 5.44 11.2 5.14 4.2 
  sample II 40.56 4.7 38.29 2.7 
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Table 3.14: Two different volumes of homogenized fecal material (2.0 mg dw/mL) were 
used for analysis of two different samples. Each sample was analyzed in fivefold. Mean 
TG species concentrations and the coefficient of variation (CV) are displayed. 
 
Volume 








TG 50:2 sample I n.d.  n.d.  
 sample II 2.13 7.7 2.05 3.4 
TG 50:1 sample I n.d.  n.d.  
 sample II 0.60 6.0 0.55 7.6 
TG 52:5 sample I n.d.  n.d.  
 sample II 1.17 6.5 1.10 4.3 
TG 52:4 sample I 0.39 8.9 0.41 5.0 
 sample II 12.21 7.4 11.68 2.8 
TG 52:3 sample I 0.29 13.2 0.30 8.0 
 sample II 37.98 7.8 36.07 3.4 
TG 52:2 sample I 0.17 21.8 0.17 6.2 
 sample II 26.57 7.8 24.97 3.4 
TG 54:6 sample I 0.48 7.9 0.53 10.0 
 sample II 12.02 7.3 11.61 3.3 
TG 54:5 sample I 0.61 10.0 0.67 9.7 
 sample II 63.32 8.0 60.25 3.1 
TG 54:4 sample I 0.55 16.0 0.60 8.2 
 sample II 107.72 7.6 102.29 2.7 
TG 54:3 sample I 0.35 26.9 0.37 10.0 
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3.1.4.4 Effect of Lipid Extraction 
 
Besides sample homogeneity, the effect of lipid extraction on DG and TG 
concentrations was also tested. One of these experiments involved variation of 
incubation time after addition of both internal standard and Bligh and Dyer mixture to 
the homogenized fecal sample. The results are shown in Table 3.15 - Table 3.17. For 
both DG and TG species, incubation time seemed to play a minor role with a plateau 
observed after 10 min incubation time. The detected concentrations varied only slightly 
after 10 min, except for sample 2 for TG species. Species profiles showed no variation 
between the different incubation times, except for TG species profile for sample 2. An 
incubation time of 60 min, as regularly used, seemed to be sufficient, and is therefore 
still used in the following experiments. Combination of different incubation times with 
additional sonication up to 3 h during extraction is shown in Table 3.18. Both incubation 
times and simultaneous treatment with sonication did not result in significant 










 Table 3.15: Four different samples were analyzed. Incubation time before phase separation varied from 0 minutes to 24 hours. Each 
sample was analyzed only once. Sum concentrations of DG and TG species for each sample are displayed.  
 



















0 minutes 34.13 28.13 37.08 14.63 7.62 8.35 11.64 49.38 
         
10 minutes 32.53 31.8 31.90 19.35 8.72 3.30 8.67 55.63 
         
20 minutes 32.62 32.71 32.67 18.74 9.87 12.22 8.83 47.26 
         
30 minutes 33.16 32.99 30.20 19.47 7.33 3.81 7.92 52.98 
         
60 minutes 32.32 32.88 29.90 19.22 7.54 5.19 7.21 48.04 
         
180 minutes 30.95 29.98 28.40 19.35 7.48 3.68 6.68 49.76 
         



























































 Table 3.16: Species profile in % total DG of the data listed in Table 3.15. 












































DG 34:3 0.6 0.6 0.6 0.6 0.5 0.6 0.6 1.3 1.4 1.3 1.3 1.3 1.3 1.4 
DG 34:2 10.4 10.1 10.1 10.1 9.9 10.1 10.3 4.9 5.0 4.9 4.9 4.9 4.9 4.9 
DG 34:1 6.5 6.1 6.2 6.3 6.3 6.1 5.9 2.9 2.9 3.0 3.0 3.0 2.9 3.2 
DG 36:5 0.9 1.0 1.1 1.0 1.0 1.1 1.2 30.0 29.6 30.0 30.4 30.3 30.1 29.3 
DG 36:4 27.0 28.3 28.4 28.3 28.1 28.5 28.3 42.6 42.7 42.4 41.8 42.0 42.3 42.7 
DG 36:3 33.4 33.8 33.2 32.6 32.8 32.9 33.2 11.3 11.5 11.6 11.8 11.7 11.7 11.5 
DG 36:2 21.2 20.1 20.6 21.2 21.3 20.8 20.5 7.0 6.9 6.8 6.9 6.9 6.8 7.0 
 












































DG 34:3 0.6 0.6 0.6 0.6 0.6 0.6 0.6 1.2 1.1 1.0 1.0 1.0 1.0 1.1 
DG 34:2 10.0 10.1 10.2 9.9 10.2 10.1 10.0 14.1 14.3 13.8 13.8 13.6 14.2 14.0 
DG 34:1 6.2 6.0 6.1 6.4 6.3 5.8 6.4 8.0 8.0 8.4 8.4 8.5 8.1 8.2 
DG 36:5 1.1 1.1 1.1 1.0 1.0 1.2 1.1 1.7 1.7 1.7 1.8 1.8 1.8 1.8 
DG 36:4 28.0 28.2 28.2 28.0 28.2 28.6 27.8 30.1 29.4 28.0 27.9 28.3 29.6 29.3 
DG 36:3 33.3 34.0 33.1 32.8 32.6 33.4 32.9 25.7 25.6 26.9 27.2 27.0 25.5 25.9 



























































Table 3.17: Species profile in % total TG of the data listed inTable 3.15.  












































TG 50:2 1.9 1.8 1.7 1.8 1.8 1.8 1.7 0.4 0.8 0.3 0.7 0.6 0.8 0.9 
TG 50:1 1.2 1.2 1.2 1.1 1.2 1.2 1.2 0.3 0.9 0.3 0.8 0.6 0.9 0.7 
TG 52:5 0.3 0.4 0.4 0.4 0.4 0.4 0.4 3.7 3.9 3.7 4.0 4.5 2.8 3.5 
TG 52:4 8.8 8.0 7.9 8.4 8.5 8.1 8.2 5.7 6.6 5.2 6.3 6.0 5.6 7.2 
TG 52:3 10.7 10.7 10.9 10.5 10.4 10.3 10.6 1.3 2.0 1.3 2.1 1.5 4.4 3.6 
TG 52:2 7.2 7.1 7.3 6.8 6.6 6.9 6.9 0.7 1.8 0.7 1.6 1.1 3.1 2.4 
TG 54:7 0.9 0.9 0.8 1.0 1.0 1.0 1.0 33.3 31.6 35.0 30.9 35.8 22.9 22.1 
TG 54:6 12.0 11.6 11.7 12.8 12.7 12.1 12.4 36.7 31.8 35.8 32.0 32.0 24.8 28.8 
TG 54:5 20.8 21.2 21.4 21.7 21.7 21.2 21.4 12.3 11.4 12.0 11.8 11.0 13.2 14.1 
TG 54:4 22.1 22.9 22.9 22.0 22.2 22.5 22.3 3.9 5.2 4.2 5.8 3.9 10.6 8.5 
TG 54:3 14.0 14.3 14.1 13.5 13.5 14.6 13.8 1.8 4.1 1.6 3.9 2.9 10.9 8.0 
 












































TG 50:2 1.5 1.7 1.8 2.0 1.7 1.7 1.8 2.6 2.5 2.6 2.6 2.6 2.6 2.7 
TG 50:1 1.0 1.0 1.2 1.2 1.1 1.2 1.2 1.1 1.0 1.1 1.1 1.1 1.1 1.1 
TG 52:5 0.3 0.4 0.4 0.4 0.4 0.4 0.4 1.1 1.1 1.1 1.1 1.1 1.1 1.1 
TG 52:4 7.8 8.2 8.5 8.6 8.3 8.3 8.2 12.0 12.2 12.0 12.1 12.1 12.1 12.1 
TG 52:3 10.2 10.2 10.7 11.0 10.3 10.4 10.3 9.3 9.2 9.4 9.5 9.3 9.2 9.1 
TG 52:2 6.3 6.0 6.7 6.7 6.6 6.9 6.7 5.4 5.2 5.6 5.6 5.6 5.5 5.9 
TG 54:7 0.8 1.0 0.9 0.9 1.0 1.0 1.0 1.5 1.6 1.5 1.5 1.5 1.5 1.6 
TG 54:6 12.8 13.2 12.7 12.4 12.5 12.4 12.4 18.0 18.4 17.7 17.7 17.7 17.7 17.4 
TG 54:5 22.7 22.4 21.9 21.6 21.6 21.6 21.5 20.3 20.4 20.2 20.1 20.1 20.4 19.7 
TG 54:4 23.0 22.8 22.0 21.9 22.7 22.2 22.6 17.5 17.2 17.4 17.4 17.4 17.4 17.4 


























































Table 3.18: Calculation of CV for DG and TG species either with or without ultrasonication during extraction. Incubation times varied 
from 10 to 180 minutes. Each sample (2.0 mg dw/mL) was analyzed in three replicates. 
 
    without ultrasonication ultrasonication 














10 minutes sample I 4.08 8.3 0.13 11.7 4.14 9.9 0.22 89.4 
 sample II 48.69 10.6 4.74 15.7 46.91 2.3 4.87 13.1 
 sample III 9.08 6.9 1.33 19.8 8.86 4.2 1.25 11 
 
 
   
 
   
 
30 minutes sample I 4.22 4.6 0.13 10.2 4.52 1.1 0.2 51.8 
 sample II 50.73 6.8 4.99 2.1 46.93 4.3 5.06 0.6 
 sample III 9.29 5.7 1.33 10.5 9.76 4.1 1.35 13.8 
 
 
   
 
   
 
60 minutes sample I 4.35 1.9 0.12 5.2 4.39 6.3 0.12 1.8 
 sample II 48.85 4.2 5.04 16.3 50.15 3.6 5 3 
 sample III 8.89 3.2 1.2 5.2 9.88 3.1 1.53 33 
 
 
   
 
   
 
120 minutes sample I 4.39 2.6 0.18 55.9 4.34 3.2 0.12 3.8 
 sample II 49.79 10.8 4.67 7.1 47.36 7.2 4.65 7.6 
 sample III 8.89 1.5 1.16 2.9 9.42 4 1.18 2.8 
  
   
 
   
 
180 minutes sample I 4.19 1.7 0.12 5 6.97 64 0.59 136 
 sample II 48.89 3.6 6.18 34.6 49.91 5.7 4.55 4.7 
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3.1.4.5 Effect of Stool Grade 
 
In a next step, we asked whether these inhomogeneity issues could be related to the 
consistency of the fecal material. Therefore, we selected, if available, three samples 
for each stool grade (according to Bristol Stool Chart (170); with grade 1 representing 
hard and grade 7 watery consistency) from a study on fibers and polyunsaturated fatty 
acids intervention (171). The samples were measured in five replicates (Table 3.19). 
Samples with grades 3 to 5 showed CVs ≤ 10%. However, in samples with lower 
grades (1 to 2) we could not see a clear trend for higher CVs, which may have been 
expected for more solid consistency.  
 
Table 3.19: DG and TG concentrations and their coefficient of variation (n=5) related 
to stool grading. 
 
    Diacylglycerol Triacylglycerol 







Grade 1 sample a 46.11 6.6 2.31 11.6 
 sample b 15.71 7.6 14.25 6.1 
 sample c 54.27 6.4 8.55 10.7 
 
 
   
 
Grade 2 sample d 78.73 7.1 10.69 10.9 
 sample e 38.65 26.3 82.10 27.6 
 sample f 11.62 2.1 1.11 20.8 
 
 
   
 
Grade 3 sample g 93.86 9.2 38.27 10.2 
 sample h 27.30 6.0 2.65 7.5 
 sample i 29.44 6.5 39.34 5.1 
 
 
   
 
Grade 4 sample j 52.35 3.0 5.15 7.9 
 sample k 14.30 5.8 1.87 6.5 
 sample l 21.41 2.7 2.15 2.5 
  
   
 
Grade 5 sample m 66.36 6.4 15.67 6.0 
 sample n 25.91 8.9 19.96 8.0 
 sample o 94.64 4.2 11.83 5.5 
  
   
 
Grade 6 sample p 65.84 4.8 10.28 5.6 
 sample q 44.92 3.8 21.40 5.2 
 sample r 49.10 17.0 39.42 15.2 
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3.1.4.6 Stability of Sample Extracts 
 
In addition to homogenization and extraction experiments, the stability of samples after 
the extraction procedure was examined. Therefore, samples were subjected to lipid 
extraction and immediately measured on the Q Exactive Orbitrap. Subsequently, the 
samples were stored at different temperatures (-80°C, -20°C, 4°C, and RT) for one 
week and measured again. For both DG and TG species the analyzed concentrations 
hardly changed. The samples therefore showed good stability and could be stored at 
different temperatures for at least one week. Data are shown in Table 3.20. 
 
Table 3.20: Concentrations of DG and TG species depending on storage at different 
temperatures for one week. Five different samples were measured. Each sample was 
analyzed only once. Samples were measured directly after lipid extraction (Reference) 
and again after one week of storage under different conditions. Sum concentrations of 
DG and TG species for each sample are displayed. 
 
sample temperatures 




sample I Reference 20.23 22.15 
 -80°C 20.95 25.72 
 -20°C 20.07 23.92 
 4°C 19.03 21.92 
 RT 19.18 21.00 
    
sample II Reference 3.34 1.13 
 -80°C 3.07 1.19 
 -20°C 3.19 1.10 
 4°C 3.25 1.10 
 RT 3.31 1.12 
    
sample III Reference 3.37 0.66 
 -80°C 2.97 0.56 
 -20°C 3.32 1.34 
 4°C 3.27 0.34 
 RT 3.49 0.36 
    
sample IV Reference 7.58 1.42 
 -80°C 6.78 1.38 
 -20°C 7.47 1.54 
 4°C 7.18 1.27 
 RT 9.19 1.58 
    
sample V Reference 0.75 0.22 
 -80°C 0.78 0.23 
 -20°C 0.74 0.22 
 4°C 0.72 0.21 
  RT 0.73 0.30 
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3.1.4.7 Summary – Homogenization and Extraction 
 
Validation of this method demonstrated its suitability for large scale studies including 
extraction, FIA-FTMS analysis, and data evaluation although a high variation was 
observed for some samples. 
 
Despite thorough mechanical homogenization, fecal samples are suspensions, and a 
lack of homogeneity can lead to deviations. Therefore, various experiments were 
performed to evaluate the underlying factors including centrifugation, bead beating, 
variation of sample concentration and volume, time of lipid extraction, ultrasonication, 
stool grade, and storage of extracted samples.  
Centrifugation of samples showed that DG species were present in similar 
concentrations in the supernatant as well as in the pellet, whereas TG species were 
detected predominantly in the pellet. Additional homogenization using Precellys® 
homogenizer resulted in a slight decrease in CV for TG species, whereas the CV for 
DG species remained constant or even slightly increased. Variation of sample 
concentration did not reduce variations. Furthermore, no improvement in 
reproducibility could be achieved by changing the incubation time during extraction or 
by ultrasonication. Analysis of the consistency of fecal material provided no clear 
evidence for correlation of CVs and stool grade. 
Only extraction of a higher sample volume resulted in lower CVs for both DG and TG 
species. After extraction samples could be stored until measurement for about one 
week. Storage temperature seemed to have little influence on the concentrations. 
However, it is recommended to store the samples at least at -20°C to avoid possible 
changes due to lipolysis.  
 
In summary, these data clearly demonstrate that homogenization is very important for 
reproducibility and accuracy of lipid quantification of human fecal material. Despite 
extensive testing, variation of concentrations for some samples was substantial. Of 
note, lipid species profiles seem to be largely unaffected by homogenization and 
extraction conditions.   
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Suitable pre-analytics is an important prerequisite for meaningful medical laboratory 
diagnostic. Many factors before, during and after sampling can have an influence on 
the test results. Storage of the samples and their transport to the laboratory are also 
important factors influencing the laboratory analysis. In practice, it is often the case 
that the raw fecal material collected from patients is not directly subjected to analysis 
but stored and transported for substantial times. In many cases the material is not 
sufficiently cooled (2 - 8°C). Hence, it is important to find a suitable additive as a 
stabiliser to prevent changing of analyte concentrations, e.g. by enzymatic reactions.  
 
3.1.5.1 Effect of Solvents 
 
In order to ensure the stability of the fecal material, we checked whether the solvent 
used for sample preparation may affect DG/TG concentrations. In several studies 
homogenization of fecal material was performed in water (172) or aqueous buffer (173, 
174) but also in diluted organic solvents (175, 176). In our laboratory, diluted 
isopropanol was used to stabilize fecal concentrations of short chain fatty acids (177), 
thus the effect of isopropanol was investigated for DG/TG concentrations. Therefore, 
fecal raw material was homogenized in water and subsequently diluted 3- to 7-fold (by 
volume) with either water or isopropanol (Figure 3.8) and immediately stored at -80°C. 
Unexpectedly, addition of isopropanol tremendously increased DG concentrations in 
almost all samples. Moreover, in two of the six samples, we observed a drop of TG 
concentrations. However, the increase of DG could not be explained by TG 
degradation in these samples because the increase of DG exceeded the decreased 
amount of TG. 
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Figure 3.8: Effect of isopropanol addition on DG (A) and TG (B) quantification. Six 
individual samples homogenized in water and supplemented with the same volume of 
either H2O (brown) or isopropanol (green) (70% related to volume) are displayed. 
 
 
Comparison of spectra of samples stabilized in water or isopropanol showed clear 
differences in all DG species profiles and in the TG profiles of three of the six samples 
(Table 3.21 and Table 3.22). We could not observe additional species upon 
isopropanol addition and no common pattern in the increased DG species for the 










 Table 3.21: Species profile in % total DG for aqueous and isopropanol-containing samples (Figure 3.8). 
 
Species 

























DG 34:3 0.6 0.6 0.0 0.4 1.0 0.9 1.3 0.9 2.1 1.6 8.7 5.3 
DG 34:2 7.1 5.9 19.2 12.8 10.8 8.6 6.1 7.2 8.4 8.2 10.0 10.7 
DG 34:1 8.6 7.0 9.5 5.7 13.5 11.8 4.5 1.9 8.1 7.8 19.1 15.0 
DG 36:5 1.3 1.4 1.1 1.7 2.5 2.3 3.7 2.1 3.9 7.9 9.1 4.5 
DG 36:4 13.3 13.0 23.5 27.1 18.3 16.3 24.4 43.6 26.5 20.9 16.2 22.9 
DG 36:3 26.3 24.6 21.8 25.6 16.3 15.5 29.4 33.0 26.4 20.7 14.4 18.5 
DG 36:2 42.8 47.5 24.9 26.7 37.5 44.6 30.6 11.3 24.7 33.0 22.4 23.1 
 
 
Table 3.22: Species profile in % total TG for aqueous and isopropanol-containing samples (Figure 3.8). 
 
Species 

























TG 52:4 3.5 3.8 14.1 14.4 5.0 4.9 5.2 8.4 6.2 9.3 4.5 7.5 
TG 52:3 4.8 5.1 8.7 8.4 3.8 3.8 5.0 5.1 3.4 6.3 6.0 5.9 
TG 52:2 9.8 10.0 7.2 7.2 12.1 12.2 4.3 2.1 10.2 6.9 15.4 11.9 
TG 54:7 0.6 0.8 1.5 1.6 1.4 1.6 4.2 5.7 9.0 7.6 1.5 1.5 
TG 54:6 5.0 5.1 17.1 16.7 7.1 7.4 11.8 22.0 7.5 14.0 8.3 13.8 
TG 54:5 9.9 9.3 16.4 15.8 5.4 5.6 23.3 32.5 8.3 14.5 7.3 11.0 
TG 54:4 23.0 22.5 14.0 13.6 13.0 12.9 23.4 18.0 11.8 14.6 14.2 14.0 



















































3.1 LIPID SPECIES PROFILE OF HUMAN FECAL SAMPLES IN POSITIVE ION MODE 
78 | P a g e  
 
To get more insight, we examined both aqueous and isopropanol containing sample 
homogenates by light microscopy (Figure 3.9). Clearly, aqueous samples seemed to 
be more homogeneous compared to isopropanol containing samples. However, in 
aqueous samples a massive presence of bacteria could be observed. To inhibit 








Figure 3.9: Comparison of human fecal sample D diluted either in water (A) or 
isopropanol (B) at a dry weight of 2.0 mg dw/mL using phase contrast microscopy with 
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In a next step, we checked whether there is a trend regarding the alcohols used 
(methanol < ethanol < isopropanol) for stabilization. Therefore, the raw fecal material 
of sample C was thawed and a part of it was homogenized and additionally dissolved 
in either MeOH or EtOH. Results are shown in Table 3.23.  
 
Table 3.23: Species profile in % total of DG and TG for sample C either in H2O, 




H2O methanol ethanol isopropanol 
  
Mean (n=3)  
[%] 
Mean (n=3)  
[%] 
Mean (n=3)  
[%] 
Mean (n=3)  
[%] 
Diacylglyerol DG 34:3 0.9 0.6 0.6 0.6 
 DG 34:2 8.9 9.0 8.8 8.6 
 DG 34:1 4.1 3.5 3.7 3.6 
 DG 36:5 0.4 0.4 0.3 0.4 
 DG 36:4 38.0 42.2 42.1 42.6 
 DG 36:3 34.7 32.4 32.8 32.6 
 DG 36:2 13.0 11.9 11.7 11.6 
      
Triacylglycerol TG 50:2 0.8 0.8 0.8 0.8 
 TG 50:1 0.2 0.2 0.2 0.2 
 TG 50:0 0.2 0.1 0.1 0.2 
 TG 52:5 0.4 0.3 0.3 0.4 
 TG 52:4 8.8 8.9 8.9 8.9 
 TG 52:3 5.5 5.4 5.4 5.5 
 TG 52:2 1.9 1.8 1.8 1.9 
 TG 54:7 0.4 0.4 0.4 0.4 
 TG 54:6 26.1 26.4 26.7 26.6 
 TG 54:5 34.2 34.3 34.3 33.9 
 TG 54:4 16.1 16.0 15.7 16.0 
  TG 54:3 5.6 5.4 5.3 5.4 
 
 
For this sample, the data did not show any trend regarding the series of alcohol. Here, 
species profiles showed only small changes between the solvents, for both DG and 
TG species. This could be already demonstrated for sample C in Figure 3.8. DG 
species with 36 carbon atoms differed slightly in H2O compared to the alcohols used. 
This trend could not be observed for TG species with 54 carbon atoms. In case of 
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For further solvent comparison, a fresh native sample was homogenized in H2O as 
described above and dried under vacuum overnight. Samples were dissolved in either 
100 µL H2O, MeOH, EtOH, or isopropanol and a standard mix was spiked to the 
different solvents’ prior extraction. The results are shown in Table 3.24. Concentration 
of DG and TG could be detected at similar levels for all solvents. For both lipid classes, 
CV showed less than 10% for all solvents, being highest for H2O. The different 
concentrations of lipids contained in samples from previous experiments could not be 




Table 3.24: Calculated CV of DG and TG sum concentrations of a sample dried for 
extraction overnight prior addition of different solvents. Reconstituted samples were 
measured in triplicates.  
 
  Diacylglycerol Triacylglycerol 
solvents 
Mean (n=3)  
[nmol/mg dw] 
CV [%] 
Mean (n=3)  
[nmol/mg dw] 
CV [%] 
H2O  1.85 9.2 6.00 10.8 
methanol 2.11 4.1 6.63 7.2 
ethanol 2.06 3.4 6.71 7.8 
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3.1.5.2 Effect of Storage Temperature 
 
Next, we asked whether there is a suitable solvent for stabilizing the fecal material 
before and after homogenization. For this experiment the same samples were used as 
described for the previous tests. The raw fecal material was collected in the morning 
and immediately brought to the laboratory including sufficient cooling, where it was 
instantly homogenized. Homogenization was carried out using the pre-analytics 
protocol described under 2.5.1 Feces Homogenization. Homogenized samples were 
then dissolved in various solvents: H2O, methanol, ethanol, or isopropanol. Some 
samples were immediately stored at -80°C while the remaining samples were stored 
at either 4°C or at RT for 30 minutes to 4 days until freezing at -80°C.  
 
In a first preliminary test feces of two different donors were dissolved in H2O, methanol, 
or isopropanol, respectively. DG species have been found to be relatively stable up to 
four days, with only minor variation that did not follow a clear trend. Concentration of 
TG species decreased rapidly after 3 h. The CVs were mostly below 15%. Some 
outliers were observed. Species profiles in %, shown in Table 3.25 - Table 3.28, 
represent the most common DG and TG species in fecal material for each sample. The 
differences between the respective times and temperatures were much less, the 
percentages fluctuated only slightly in some cases. However, there were several 
exceptions, especially when samples were stored at 4°C or RT for more than one day. 
Methanol seemed to be less stable than H2O or isopropanol.  
From this it could be concluded that the total concentrations of the two lipid classes 












 Table 3.25: Species profile in % total DG. Data of sample A for either H2O, methanol or isopropanol are displayed.  
 
  Sample A 
  H2O 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
DG 34:3 0.3 0.3 0.1 0.4 0.2 0.6 8.9 0.4 0.4 0.3 0.5 0.7 0.3 
DG 34:2 10.5 10.1 10.5 10.2 10.5 12.1 15.4 10.8 9.4 10.5 10.7 10.7 10.5 
DG 34:1 3.9 4.3 4.2 3.4 3.3 2.9 31.2 2.8 2.5 2.7 2.4 2.7 2.2 
DG 36:5 0.5 0.8 0.7 0.5 0.4 1.5 n.d. 0.9 1.1 1.1 1.2 1.4 1.1 
DG 36:4 46.7 44.7 45.2 47.3 46.7 47.2 10.2 47.0 46.6 47.5 47.5 47.3 49.3 
DG 36:3 28.1 29.4 28.8 28.9 29.0 26.7 16.0 28.4 30.0 27.7 27.9 27.3 26.8 
DG 36:2 9.9 10.4 10.4 9.4 10.0 8.9 18.3 9.6 10.0 10.3 9.9 9.9 9.8 
 
 
  Sample A 
  Methanol 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
DG 34:3 0.8 0.9 1.8 2.2 2.0 2.3 8.7 1.3 1.8 1.3 2.0 2.6 6.1 
DG 34:2 11.4 11.2 11.0 10.8 11.0 12.0 5.0 10.8 10.5 10.1 10.6 10.2 11.5 
DG 34:1 2.0 2.1 1.6 1.6 1.4 1.5 19.4 0.7 1.5 1.8 1.9 3.0 1.8 
DG 36:5 1.6 1.5 3.9 4.8 5.7 7.3 6.1 4.6 4.2 4.1 4.1 4.7 6.9 
DG 36:4 45.3 44.7 45.8 40.2 35.9 21.1 53.1 45.1 44.3 43.1 37.7 27.0 13.7 
DG 36:3 29.4 30.0 30.1 34.3 36.0 45.9 2.4 31.9 31.8 32.0 34.0 41.7 48.5 




























































 Sample A 
 Isopropanol 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
DG 34:3 0.6 0.6 0.6 0.6 0.7 0.7 1.6 0.6 0.6 0.6 0.6 0.7 0.7 
DG 34:2 10.3 10.1 10.1 10.5 10.5 10.9 19.8 10.6 10.3 10.6 10.2 10.5 10.4 
DG 34:1 1.6 1.4 1.5 1.5 1.4 1.3 38.4 1.6 1.5 1.6 1.6 1.4 1.4 
DG 36:5 1.1 1.1 1.2 1.2 1.3 1.3 1.1 1.2 1.1 1.1 1.2 1.3 1.3 
DG 36:4 49.5 50.7 50.2 50.2 49.9 50.6 11.1 49.7 50.4 50.1 50.4 50.8 51.2 
DG 36:3 28.4 28.4 28.3 28.4 28.1 26.8 14.6 27.8 28.1 27.4 27.7 27.1 27.2 



























































Table 3.26: Species profile in % total DG. Data of sample B for either H2O, methanol or isopropanol are displayed. 
 
  Sample B 
  H2O 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
DG 34:3 0.8 0.8 0.8 0.6 0.7 0.5 0.6 0.8 0.8 1.0 1.1 1.0 1.0 
DG 34:2 7.0 5.7 6.2 7.9 7.9 7.2 8.4 5.9 5.1 7.6 7.9 9.2 9.0 
DG 34:1 2.8 2.5 2.5 2.7 2.7 2.7 2.7 2.4 2.4 2.7 2.8 3.1 3.1 
DG 36:5 4.7 6.4 5.3 3.5 3.9 3.9 3.1 7.0 8.2 4.9 5.2 3.9 3.6 
DG 36:4 37.2 36.9 37.7 37.5 39.3 37.6 38.7 37.5 36.6 38.2 38.7 39.4 40.2 
DG 36:3 32.6 33.6 33.0 32.1 30.3 32.0 31.1 33.1 33.6 30.9 30.0 27.9 28.2 
DG 36:2 14.8 14.1 14.5 15.6 15.2 16.1 15.4 13.2 13.4 14.6 14.3 15.5 15.0 
 
 
  Sample B 
  Methanol 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
DG 34:3 2.4 2.5 2.3 2.4 2.3 2.1 1.5 2.5 2.4 2.2 2.0 1.6 2.0 
DG 34:2 9.1 8.9 8.5 8.7 8.6 10.3 13.3 8.6 8.8 8.9 8.6 8.8 9.9 
DG 34:1 1.9 2.0 2.0 2.0 2.5 5.6 11.4 1.6 1.8 2.0 1.7 2.1 3.5 
DG 36:5 7.2 7.4 7.6 7.8 7.4 5.2 1.2 7.9 7.2 6.7 7.3 6.2 4.6 
DG 36:4 49.7 51.0 51.1 50.2 48.6 40.2 39.9 51.6 51.6 50.0 53.4 52.9 43.5 
DG 36:3 22.1 21.1 21.5 21.8 22.6 25.0 24.3 21.2 21.4 22.2 20.8 21.6 26.4 































































  Sample B 
  Isopropanol 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
DG 34:3 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.2 1.2 1.2 1.2 1.2 
DG 34:2 8.6 8.6 8.5 8.4 8.4 8.6 9.1 8.6 8.6 8.5 8.4 8.3 8.3 
DG 34:1 2.3 2.3 2.2 2.3 2.2 2.3 2.6 2.2 2.2 2.2 2.3 2.1 2.1 
DG 36:5 3.4 3.3 3.2 3.3 3.4 3.3 3.6 3.3 3.2 3.3 3.1 3.3 3.3 
DG 36:4 44.8 44.8 44.8 44.8 44.7 43.5 42.3 45.1 44.9 45.2 44.3 45.1 45.3 
DG 36:3 26.5 26.5 26.8 26.7 27.3 27.9 27.8 26.4 26.7 26.5 26.9 26.7 26.9 


























































 Table 3.27: Species profile in % total TG. Data of sample A for either H2O, methanol or isopropanol are displayed. 
 
  Sample A 
  H2O 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
TG 50:2 1.4 1.3 1.3 1.2 1.1 2.9 4.4 1.2 1.1 1.2 1.1 1.2 1.2 
TG 50:1 0.9 0.5 0.6 0.5 0.5 0.1 6.4 0.4 0.3 0.4 0.3 0.2 0.2 
TG 52:5 0.5 0.5 0.5 0.5 0.5 1.3 71.4 0.5 0.5 0.5 0.6 0.6 0.5 
TG 52:4 27.5 21.8 26.0 24.9 22.5 19.7 n.d. 18.9 15.1 16.6 16.3 13.6 16.0 
TG 52:3 2.3 3.2 2.5 2.6 2.9 3.8 2.4 3.7 4.5 4.3 4.1 4.8 4.6 
TG 52:2 2.3 2.0 2.2 1.9 1.8 1.4 4.0 1.6 1.5 1.5 1.5 1.6 1.5 
TG 54:7 0.6 1.0 0.7 0.5 0.6 1.7 2.0 0.7 0.7 0.9 0.8 0.9 0.9 
TG 54:6 26.5 28.3 26.8 28.2 29.3 31.0 2.6 30.7 30.4 31.4 31.6 30.7 31.1 
TG 54:5 24.8 26.6 25.4 26.6 27.3 25.5 3.3 28.5 30.8 29.6 29.8 29.7 29.1 
TG 54:4 10.2 11.2 10.5 10.3 10.6 10.1 1.7 11.1 12.3 11.2 11.2 12.6 11.7 




























































  Sample A 
  Methanol 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
TG 50:2 1.6 1.4 2.1 2.8 2.7 3.6 5.9 2.0 1.8 1.6 1.7 2.1 3.0 
TG 50:1 0.2 0.1 1.1 1.9 2.0 3.4 7.8 0.8 0.8 0.6 0.5 0.7 3.5 
TG 52:5 0.8 0.7 0.8 0.7 0.7 0.5 n.d. 0.6 0.6 0.5 0.5 0.7 0.2 
TG 52:4 12.8 12.1 19.1 26.7 29.6 50.5 30.2 19.0 16.8 13.3 13.5 14.2 53.1 
TG 52:3 5.9 5.9 5.4 4.1 3.7 0.2 2.9 4.9 5.5 6.0 6.4 7.4 n.d. 
TG 52:2 2.3 2.0 3.3 4.7 5.1 6.6 33.1 3.1 3.0 2.7 3.0 3.2 5.7 
TG 54:7 1.2 1.7 1.2 1.0 1.0 0.1 0.9 0.8 0.8 0.7 0.8 1.2 1.5 
TG 54:6 28.9 28.6 24.8 19.7 16.8 9.9 3.7 25.7 25.7 25.5 23.2 21.6 7.0 
TG 54:5 29.3 30.9 25.5 22.3 20.5 12.1 4.7 26.3 27.6 30.0 29.5 27.6 11.1 
TG 54:4 12.8 12.8 12.2 11.1 12.1 8.0 5.8 12.5 13.3 14.5 15.6 15.7 8.9 
TG 54:3 4.3 3.7 4.4 5.0 5.9 5.3 5.0 4.2 4.2 4.7 5.1 5.6 6.0 
 
  Sample A 
  Isopropanol 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
TG 50:2 1.4 1.3 1.4 1.4 1.3 1.6 0.0 1.4 1.3 1.4 1.4 1.3 1.6 
TG 50:1 0.1 0.1 0.1 0.1 0.1 0.4 25.6 n.d. n.d. n.d. 0.1 0.1 0.6 
TG 52:5 0.8 0.9 0.9 0.9 0.9 1.1 n.d. 0.9 0.9 1.0 1.1 1.2 1.3 
TG 52:4 13.1 13.2 13.3 13.4 13.3 13.6 n.d. 13.4 13.3 13.7 13.6 13.8 13.7 
TG 52:3 4.9 4.4 4.6 5.2 4.4 5.1 8.4 4.6 4.4 4.4 4.7 4.2 4.7 
TG 52:2 1.3 1.2 1.3 1.3 1.3 1.6 12.2 1.1 1.1 1.2 1.1 1.1 1.5 
TG 54:7 1.4 1.5 1.5 1.4 1.6 1.8 4.5 1.6 1.7 1.7 1.7 2.2 2.1 
TG 54:6 34.0 36.3 34.5 33.2 35.1 34.7 15.5 34.9 35.8 36.0 35.2 37.8 36.1 
TG 54:5 30.4 29.6 29.9 29.8 29.4 27.4 19.1 30.0 30.0 28.9 29.6 26.2 24.6 
TG 54:4 9.8 9.0 10.0 10.7 9.9 9.1 7.3 9.6 9.0 9.1 9.3 8.8 8.8 


























































Table 3.28: Species profile in % total TG. Data of sample B for either H2O, methanol or isopropanol are displayed. 
 
  Sample B 
  H2O 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
TG 50:2 0.9 0.9 0.9 0.9 0.9 0.9 1.0 1.0 0.8 0.9 1.0 1.3 1.0 
TG 50:1 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 
TG 52:5 0.5 0.7 0.6 0.4 0.4 0.4 0.5 0.6 0.9 0.6 0.5 0.8 0.5 
TG 52:4 9.2 9.2 9.3 10.1 10.1 8.5 10.2 10.5 8.5 9.2 10.0 11.1 10.2 
TG 52:3 5.7 5.5 5.6 5.5 5.0 5.0 5.7 5.1 5.6 5.5 5.8 5.2 5.5 
TG 52:2 2.9 2.8 2.6 2.6 2.4 3.8 2.9 2.2 2.4 3.5 2.6 3.0 2.7 
TG 54:7 1.3 3.4 2.0 0.7 0.7 1.0 0.9 1.5 3.9 1.6 1.5 2.2 1.1 
TG 54:6 25.1 24.1 24.5 26.0 28.4 22.9 24.9 29.3 23.9 24.0 24.8 24.7 26.6 
TG 54:5 28.9 28.1 28.9 29.3 29.3 24.9 28.0 29.0 29.5 26.9 29.6 26.9 28.4 
TG 54:4 16.0 16.0 16.6 15.2 15.4 13.8 15.6 13.9 16.8 15.3 15.4 14.6 15.2 











































































  Sample B 
  Methanol 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
TG 50:2 5.5 9.5 2.9 10.4 5.3 1.8 6.8 14.2 1.6 1.7 9.0 5.5 1.2 
TG 50:1 0.5 0.6 0.4 0.6 0.8 0.4 1.0 0.8 0.2 0.2 1.4 0.9 0.3 
TG 52:5 1.4 1.9 0.8 1.4 1.3 0.9 0.3 2.3 1.2 1.0 1.7 0.9 0.5 
TG 52:4 12.5 15.8 9.3 14.1 14.1 10.4 30.9 17.7 10.4 10.1 14.8 13.5 10.3 
TG 52:3 6.5 6.8 6.2 6.3 6.3 5.6 2.5 7.0 6.3 6.5 6.4 6.8 6.8 
TG 52:2 2.9 3.3 4.0 3.3 3.9 4.6 3.7 3.8 2.6 2.6 4.1 3.5 3.1 
TG 54:7 3.5 n.d. 1.7 11.2 n.d. 0.9 14.5 n.d. 5.5 2.5 n.d. n.d. 0.9 
TG 54:6 25.1 24.3 21.5 17.5 22.6 22.9 10.1 19.8 23.4 24.3 20.3 19.6 22.4 
TG 54:5 22.9 19.5 26.2 17.2 21.7 21.5 14.3 16.1 25.7 28.3 19.6 22.8 28.4 
TG 54:4 11.8 10.8 14.9 9.1 12.6 13.0 9.2 10.2 13.9 15.2 12.6 14.7 16.8 
TG 54:3 7.5 7.4 12.1 8.9 11.5 18.1 6.6 8.2 9.1 7.6 9.9 11.8 9.3 
 
  Sample B 
  Isopropanol 


























[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
TG 50:2 1.1 1.0 1.0 1.0 1.1 1.1 3.0 1.0 1.0 1.1 1.0 1.0 1.0 
TG 50:1 0.2 0.2 0.1 0.2 0.2 0.4 5.7 0.1 0.1 0.1 0.1 0.2 0.4 
TG 52:5 0.8 0.8 0.8 0.9 0.9 1.0 4.4 0.9 0.9 0.9 0.9 1.1 1.3 
TG 52:4 10.9 10.6 10.7 10.8 11.3 10.9 10.3 10.8 10.8 10.8 10.7 11.2 11.3 
TG 52:3 5.2 5.1 5.1 5.1 5.3 5.2 5.8 5.1 4.9 4.7 4.5 4.0 4.1 
TG 52:2 2.5 2.5 2.4 2.4 2.4 2.4 3.4 2.4 2.3 2.3 2.1 1.9 1.5 
TG 54:7 3.4 3.4 3.4 3.6 3.9 4.3 7.3 3.5 3.5 3.7 4.1 5.1 5.8 
TG 54:6 26.8 26.5 27.1 27.9 28.4 28.4 20.3 27.6 27.5 27.9 29.2 31.9 34.3 
TG 54:5 28.0 28.1 27.7 27.0 26.8 26.1 20.7 27.7 28.1 28.2 28.1 26.8 25.0 
TG 54:4 13.3 13.6 13.5 13.0 12.3 12.1 11.1 13.2 13.1 12.7 12.2 10.7 10.0 

















































3.1 LIPID SPECIES PROFILE OF HUMAN FECAL SAMPLES IN POSITIVE ION MODE 




Figure 3.10: Schematic illustration of DG and TG concentrations in H2O (left) and 
isopropanol (right) at either 4°C (above) or at room temperature (RT, below) between 
60 minutes and 4 days. Mean values of three different samples are shown. 
 
 
As the data in Table 3.21, Table 3.22 and Figure 3.8 already showed, the addition of 
isopropanol significantly increased DG concentrations in almost all samples. Whereas 
DG species seemed to be stable in water, the concentrations in isopropanol changed 
tremendously; in four of six samples the concentration even increased during the day. 
Each sample behaved differently. The storage temperature seemed to have a minor 
influence on the concentration, although no clear trend was apparent.  
Concentration between the two solvents differed for TG species. All samples in 
isopropanol showed a considerable drop of TG concentration after 24 hours after 
homogenization. However, the concentration in water seemed to be stable for most 
samples (Data shown in Table 3.29, Table 3.30, and Figure 3.10). Again, the increase 
of DG could not be explained by TG degradation in these samples because the 











Table 3.29: DG concentrations of six different samples in either H2O or isopropanol are displayed. The samples were stored at three 





  sample A sample B sample C sample D sample E sample F 
temperature time H2O Isopropanol H2O Isopropanol H2O Isopropanol H2O Isopropanol H2O Isopropanol H2O Isopropanol 
 -80°C  1.37 3.99 1.60 8.08 2.84 4.06 6.49 50.83 0.23 28.86 1.84 352.75 
              
4°C 60 minutes 1.18 5.79 1.55 8.65 2.92 5.22 6.42 61.15 0.16 35.09 5.83 594.29 
 240 minutes 1.62 10.49 1.51 8.35 2.98 7.21 6.46 67.23 0.18 32.41 1.49 644.35 
 1 day 1.02 9.31 1.25 8.76 2.69 14.22 5.85 38.82 0.29 27.68 2.16 337.44 
 4 days 0.91 8.97 1.05 7.63 2.23 15.33 5.04 28.34 0.22 2.34 1.19 108.01 
              
RT 60 minutes 1.50 5.46 1.42 8.93 3.05 4.87 5.69 62.40 0.30 36.13 11.30 686.68 
 240 minutes 1.27 8.49 1.39 8.62 2.89 6.65 5.11 67.09 0.17 34.08 4.54 536.52 
 1 day 1.12 11.79 1.16 8.67 2.86 13.05 5.10 71.33 0.40 40.32 4.34 653.77 
  4 days 1.13 13.68 1.10 8.78 2.38 18.53 5.34 50.90 0.16 38.37 4.15 676.08 





































































Table 3.30: TG concentrations of six different samples in either H2O or isopropanol are displayed. The samples were stored at three 





  sample A sample B sample C sample D sample E sample F 
temperature time H2O Isopropanol H2O Isopropanol H2O Isopropanol H2O Isopropanol H2O Isopropanol H2O Isopropanol 
-80°C  12.84 12.39 9.40 6.13 17.37 17.99 78.34 52.01 0.17 8.48 5.06 70.35 
              
4°C 60 minutes 11.11 10.22 8.79 5.07 15.99 17.91 80.78 21.35 0.19 5.56 13.35 43.65 
 240 minutes 12.10 2.81 8.12 4.60 17.01 15.12 77.57 13.15 0.20 3.69 7.15 23.37 
 1 day 9.00 7.78 5.65 3.35 14.81 6.25 80.14 8.24 0.38 0.44 7.33 2.74 
 4 days 10.23 1.79 5.14 1.64 14.27 2.32 73.86 6.85 1.63 1.51 5.38 0.36 
              
RT 60 minutes 12.85 11.13 6.58 5.73 16.37 16.31 71.57 27.34 0.41 7.61 10.65 68.08 
 240 minutes 10.20 7.90 5.62 4.43 15.68 17.72 77.79 21.28 0.38 6.76 9.83 73.32 
 1 day 10.79 4.28 3.92 4.18 15.90 9.35 71.03 22.18 0.72 1.79 15.74 24.94 
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3.1.5.3 Effect of Freeze/Thaw Cycle 
 
To investigate the reason for the increase of DG concentrations in isopropanol, a new 
specimen was freshly homogenized and stored again at different conditions. This time 
the samples were extracted immediately afterwards and the remaining sample material 
was stored at -80°C (except the reference samples, Table 3.31). A significant 
difference in concentration could already be observed in the fresh sample material and 
changed tremendously after freezing. Whereas the samples in H2O, for both DG and 
TG species, showed an increased concentration after freezing, TG concentrations 
again decreased in isopropanol. Again, the aqueous samples seemed to be more 
stable before and after freezing.  
The increase of DG upon H2O and isopropanol addition seemed to be related to both 
disruption of bacteria resulting in improved extractability of DG and lipolysis of TG. The 
latter seemed to be triggered by addition of isopropanol in some samples and matched 
lipolytic activities observed in organic solvents (167, 168). These data clearly 
demonstrate that further studies are warranted to evaluate optimal pre-analytic 











Table 3.31: Sum concentrations are listed for DG and TG species of sample C. The sample was homogenized and stored at different 
temperatures between 60 minutes and 4 days. Samples were extracted and measured directly after homogenization (fresh sample) as 
well as after freezing (sample after freezing).  
 
   sample C 
    Diacylglycerol Triacylglycerol 
temperature time 

















 -80°C  6.49 50.8 14.57 24.58 78.34 52.01 102.14 35.46 
          
4°C 60 minutes 6.42 61.15 13.30 35.03 80.78 21.35 95.84 21.23 
 240 minutes 6.46 67.23 12.09 35.32 77.57 13.15 90.48 19.03 
 1 day 5.85 38.82 9.83 24.45 80.14 8.24 87.06 7.18 
 4 days 5.04 28.34 9.74 24.69 73.86 6.85 74.71 4.68 
          
RT 60 minutes 5.69 62.40 11.56 37.96 71.57 27.34 95.57 23.34 
 240 minutes 5.11 67.09 11.21 34.74 77.79 21.28 83.50 17.63 
 1 day 5.10 71.33 10.55 27.48 71.03 22.18 86.75 14.38 
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3.1.5.4 Effect of Sample Preparation 
 
Finally, we checked whether there is a possibility to stabilize DG and TG 
concentrations over several days by addition of SDS (0.1%, 1.0%, 2.0%, and 3.0%) as 
shown in Table 3.32. The samples were stored at different conditions again as 
described before. Concentrations for DG and TG decreased despite the addition of 
SDS; hence this detergent is not suitable as a stabilizer. Deviation of the double values 
of DG species was below 12% for all samples, whereas it was below 21% for TG 
species, indicating at least an acceptable technical reproducibility.  
 
Table 3.32: An isopropanol containing sample was analyzed without SDS as well as 
after addition of four different SDS concentrations. The sample was measured twice. 
Mean DG and TG species concentrations and the coefficient of variation are displayed.  
 
    Diacylglycerol Triacylglycerol 
SDS time 
Mean (n=2)  
[nmol/mg dw] 
Mean (n=2)  
[nmol/mg dw] 
without SDS 0 minutes 84.03 19.72 
 60 minutes 88.37 14.40 
 240 minutes 75.03 12.84 
 1 day 60.33 9.54 
 4 days 40.77 6.35 
    
0.1% 0 minutes 88.90 15.53 
 60 minutes 79.04 12.24 
 240 minutes 87.84 13.32 
 1 day 68.95 10.45 
 4 days 51.23 5.01 
    
1.0% 0 minutes 91.41 15.78 
 60 minutes 92.38 12.38 
 240 minutes 84.98 12.80 
 1 day 45.69 6.99 
 4 days 56.71 5.00 
    
2.0% 0 minutes 64.82 10.31 
 60 minutes 104.79 13.47 
 240 minutes 92.00 24.95 
 1 day 70.11 10.31 
 4 days 61.03 4.94 
    
3.0% 0 minutes 86.14 16.83 
 60 minutes 94.41 14.00 
 240 minutes 103.50 14.36 
 1 day 69.86 9.82 
  4 days 49.65 4.32 
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3.1.5.5 Effect of Intra-Individual Variance 
 
As mentioned above, 20 different samples were measured in a first step and analyzed. 
A high heterogeneity of the samples could be observed. DG and TG species were 
strongly sample-dependent in the number and type of species detected. Therefore, we 
asked whether DG and TG species profile possibly changed for one individual person, 
whose raw fecal material was collected on different days (intra-individual variance). 
 
 
Table 3.33: DG and TG sum concentrations of homogenized fecal material from three 
different, healthy voluntary donors are displayed. The raw feces were collected on five 
different days. Each sample was analyzed only once.  
 
   
Volunteer A Volunteer B Volunteer C 
DG sum TG sum DG sum TG sum DG sum TG sum 
[nmol/mg dw] [nmol/mg dw] [nmol/mg dw] [nmol/mg dw] [nmol/mg dw] [nmol/mg dw] 
day 1 4.53 0.22 1.34 0.48 2.71 0.32 
day 2 1.06 0.12 9.35 1.51 2.09 0.59 
day 3 18.99 3.81 0.97 0.41 5.88 3.20 
day 4 5.48 4.43 0.77 0.16 6.24 2.53 
day 5 4.30 1.35 0.95 0.97 4.30 0.42 
 
 
For this experiment samples were collected and analyzed from three voluntary donors 
on five different days. The sum concentrations for DG and TG of the respective donors 
are shown in Table 3.33. For volunteer A, for example, the DG concentration on day 3 
was three times higher in comparison to the other days. This could also be seen for 
volunteer B and C. Even the species profile in % (Table 3.34 and Table 3.35) showed 
significant variations for both DG and TG species. Since this experiment did not provide 
any information regarding diet, medication, or stool grades, it is difficult to determine 
the exact cause of these deviations. For subsequent experiments dealing with this 
topic, potential influence factors should be recorded in order to draw exact conclusions 













Table 3.34: Species profile in % total DG of the data listed in Table 3.33. 
Species 
Volunteer A Volunteer B Volunteer C 
day 1 day 2 day 3 day 4 day 5 day 1 day 2 day 3 day 4 day 5 day 1 day 2 day 3 day 4 day 5 
[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
DG 34:3 0.6 2.0 0.1 0.2 0.6 1.3 0.5 2.0 3.2 2.3 1.8 2.3 1.9 1.6 1.4 
DG 34:2 11.7 12.0 2.2 2.6 6.3 9.4 7.0 9.2 5.8 7.9 11.4 11.9 8.9 6.4 13.7 
DG 34:1 2.2 22.4 9.0 9.5 7.6 7.2 4.9 8.1 12.7 8.9 5.3 4.9 3.7 6.2 2.8 
DG 36:5 0.7 1.8 0.1 0.2 1.2 1.7 1.1 3.7 5.0 4.0 8.8 8.7 5.7 4.0 4.4 
DG 36:4 52.0 27.6 4.3 4.9 18.7 30.9 26.9 29.2 46.2 34.7 38.5 40.7 40.2 31.1 43.9 
DG 36:3 22.3 13.7 17.3 16.5 24.4 28.8 27.4 18.6 10.3 19.3 22.7 20.2 25.5 21.2 23.8 
DG 36:2 10.5 20.6 66.9 66.1 41.3 20.7 32.2 29.1 16.8 22.9 11.6 11.4 14.1 29.5 10.0 
 
 
Table 3.35: Species profile in % total TG of the data listed in Table 3.33. 
Species 
Volunteer A Volunteer B Volunteer C 
day 1 day 2 day 3 day 4 day 5 day 1 day 2 day 3 day 4 day 5 day 1 day 2 day 3 day 4 day 5 
[%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] [%] 
TG 50:2 2.3 6.7 0.4 0.5 0.8 1.2 1.2 2.7 2.2 5.3 2.5 2.3 1.4 1.2 2.6 
TG 50:1 2.6 15.5 1.0 1.3 1.6 5.9 0.9 5.3 7.7 27.3 2.1 1.8 0.5 1.8 1.2 
TG 50:0 6.8 29.9 0.0 0.5 1.6 56.0 0.2 35.1 51.6 31.9 2.5 2.1 n.d. n.d. 0.8 
TG 52:3 5.6 2.6 3.3 3.4 4.0 3.0 5.8 4.8 0.0 1.9 8.0 6.7 6.9 4.5 8.3 
TG 52:2 3.4 14.9 11.4 11.9 11.4 6.4 8.3 8.8 7.4 5.2 5.8 4.7 4.1 14.1 4.4 
TG 54:7 0.9 n.d. 0.1 0.0 0.3 0.1 0.5 0.7 0.2 0.7 8.7 10.0 4.4 2.2 4.5 
TG 54:6 30.2 7.7 1.5 1.0 3.1 3.4 10.7 3.4 2.3 4.7 21.1 20.1 27.6 6.8 23.5 
TG 54:5 23.5 7.7 4.9 4.4 7.7 6.8 18.1 6.2 3.4 5.7 22.5 16.4 26.3 8.3 27.1 
TG 54:4 17.7 6.9 18.0 16.9 18.9 8.5 16.8 7.8 7.4 6.6 14.9 17.1 17.3 12.1 18.4 
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3.1.5.6 Evaluation of Background 
 
Finally, the influence of different tubes used during homogenization (gentleMACSTM 
tubes, Sarstedt tubes, and Eppendorf tubes) was investigated for different solvents. 
None of the materials contained larger amounts of DG and TG species and therefore 
could be further used for homogenization (data not shown). Internal standard blanks 
were used for background correction. The solvents used for analysis (H2O, MeOH, 
EtOH, and isopropanol) were spiked with a defined amount of IS and subjected to the 
described extraction without matrix. None of the solvents used showed significant 
concentrations for lipid species found in fecal material (data not shown). Therefore, an 
influence of the background for all solvents could be excluded.  
 
3.1.5.7 Summary – Pre-Analytics 
 
Currently, we cannot explain the aggregation induced by addition of isopropanol, as 
mentioned before. The increase of DG upon isopropanol addition seemed to be related 
to both lipolysis of TG species and disruption of bacteria resulting in improved 
extractability of DG species.  
Concentrations of DG and TG species in fecal material were stable in H2O for at least 
one day at RT, whereas in isopropanol the concentration already changed after one to 
three hours.  
Besides that, preliminary data showed that already one freeze-thaw cycle seemed to 
influence the concentrations of both lipid classes. Homogenization in H2O showed 
higher concentrations after freezing, possibly due to increased extractability.  
Using SDS as stabilizer did not stabilize concentrations substantially. 
Together, these data suggest that for DG/TG quantification fecal samples should be 
collected natively and homogenized in water but not in isopropanol. Clearly, further 
experiments are needed to evaluate pre-analytics in more detail.  
Preliminary data suggest a high intra-individual variance of both DG and TG 
concentrations and species profiles. This may be related to diet but clearly needs 
further evaluation.  
In summary, these data clearly demonstrate that pre-analytics is very important for 
stability, homogenization, and analysis of human fecal material and that further studies 
are warranted to changes in DG/TG concentrations. 
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3.2. Lipid Species Profile of Human Fecal Samples in Negative Ion Mode 
 
In order to obtain better results for lyso-phospholipids and glycerophospholipids, 
further tests were carried out to enhance ionisation in negative ion mode. Extraction of 
the samples was again performed according to the protocol by Bligh and Dyer. 
Samples were resuspended using different solvents and additives before 
measurement on the Q Exactive Orbitrap. Table 3.36 lists the solvent combinations 
used with the corresponding additives and additive concentrations. In a first step, an 
internal standard mix (see Table 3.37) was analyzed using different solvents: LM1 
(178), LM3 a/b (179), LM4 (180), and LM6 (124). Instead of ammonium acetate as 
described in (178), LM1 was spiked with ammonium formate.  
 
 
Table 3.36: Comparison of different solvents, additives, and concentrations for 
measurements in negative ion mode. Solvents containing methylamine were either 
prepared from aqueous (a) or EtOH-containing (b) solutions. Experiments using LM2 





Solvent Additive Concentration 










































ammonium formate 7.5 mM 
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Table 3.37: Internal Standard (IS) including respective m/z values for [M-H]- ions 
applied in negative ion mode analysis, as well as the intensities obtained from different 
solvents (LM1, LM3 a, LM3 b, LM4, and LM6) are displayed. Methylamine 
concentration was set to 0.005% for LM3 a and LM3 b.  
 
Species m/z [M-H]- LM1 LM3 a LM3 b LM4 LM6 
FA 13:0 213.1860 1.64E+05 1.20E+06 2.94E+07 3.73E+05 5.17E+04 
FA 18:0 283.2643 4.96E+06 1.34E+08 1.75E+08 1.98E+07 1.01E+07 
FA 18:2 279.2330 1.82E+07 2.41E+08 3.18E+08 3.19E+07 2.41E+07 
FA 20:4 303.2330 8.50E+07 2.65E+08 3.48E+08 4.23E+07 8.43E+07 
FA 23:0 353.3425 7.14E+05 2.49E+06 6.61E+07 8.30E+05 2.51E+04 
MG 13:0 287.2227 6.26E+05 7.97E+06 1.94E+06 6.46E+05 4.67E+04 
MG 19:0 371.3167 5.19E+06 2.57E+07 5.87E+06 1.51E+06 1.25E+06 
DG 28:0 511.4368 8.10E+05 8.73E+06 2.16E+06 2.88E+05 1.67E+05 
DG 40:0 679.6246 2.54E+06 6.68E+06 1.25E+06 1.55E+05 1.78E+06 
LPE 13:0 410.2313 2.14E+06 6.76E+06 7.16E+06 8.42E+06 4.38E+06 
PE 28:0 634.4453 1.39E+07 3.24E+07 3.38E+07 3.66E+06 2.22E+07 
PE 40:0 802.6331 8.21E+06 1.97E+07 1.97E+07 1.64E+06 9.07E+06 
PG 28:0 665.4399 7.78E+06 3.33E+07 3.41E+07 4.89E+07 1.75E+07 
PG 40:0 833.6277 7.66E+06 3.01E+07 3.06E+07 3.54E+07 1.16E+07 
PI 34:0 837.5499 5.37E+06 1.70E+07 1.58E+07 1.40E+07 7.85E+06 
PS 28:0 678.4352 9.11E+06 6.98E+07 5.31E+07 2.28E+07 7.38E+06 
PS 40:0 846.6230 8.43E+06 5.23E+07 4.45E+07 2.06E+07 6.96E+06 
HexCer 30:1;2 642.4950 1.76E+06 7.41E+05 9.00E+04 2.32E+04 2.31E+06 
HexCer 35:1;2 712.5733 1.60E+06 5.90E+05 7.85E+04 1.66E+04 2.06E+06 
Cer 32:1;2 508.4735 4.11E+06 3.00E+06 5.51E+05 2.44E+05 4.03E+06 
Cer 35:1;2 550.5205 5.12E+06 4.09E+06 7.56E+05 3.17E+05 4.82E+06 
 
Highest intensities could be found for PC, LPC, Cer, and HexCer internal standards 
while using LM1 or LM6, respectively (data not shown). This could be explained by the 
addition of ammonium formate, which favours the formation of formate adduct ions of 
these lipid species in negative ion mode. For other phospholipid classes and especially 
for free fatty acyls, the data in Table 3.37 showed a significant increase in intensity for 
LM3 a/b (0.005% MA). This in turn could be associated with the addition of 
methylamine (MA) since it supports deprotonation of these lipid classes. In this case, 
the addition of trimethylamine did not result in significant improvement compared to 
methylamine (see also Figure 3.11). In addition, several methylamine concentrations 
were tested using LM3 a/b (MeOH/CHCl3 (5:1 v/v)): 0.005%, 0.01%, 0.05%, and 0.1%), 
showing highest intensities for 0.005% MA (data not shown). For this reason, 0.005% 
MA was added to all previously described solvent combinations for following 
experiments. LM6 which is used as standard solvent in our laboratory served as a 
reference for each test. 
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Figure 3.11: Bar charts of [M-H]- ions of lyso-phospholipid species, phospholipids, and 
FA species analyzed in negative ion mode are displayed. Samples were measured 
once each in different solvents, see Table 3.36. The corresponding adducts are listed 
in Table 3.37.  
 
3.2.1 Evaluation of Lipid Species in Plasma 
 
In order to evaluate the addition of bases, tests were carried out using plasma samples 
instead of fecal material. Numerous studies have already been published dealing with 
plasma, showing lipid species typically present in this sample material (181). For feces, 
only a few studies have been published to date (154) and it is still unclear, whether 
glycerophospholipids are present in sufficient amounts. 
Three different aspects were considered regarding this experiment. First, different 
solvents were compared (LM2 a, LM3 a, LM5 a, LM7 a, and LM6, see Table 3.36). 
Second, a comparison between methylamines in each stock solution (H2O and EtOH) 
was made, and finally the different methylamine concentrations in aqueous and 
ethanol-containing solutions were compared (0.005%, 0.01%, 0.5%, and 0.1%), see 
Table 3.38.  
Data of this measurement reflected the results explained at the beginning. LM3 b 
(MeOH/CHCl3 (5:1 v/v) with 0.005% methylamine) showed best results for lipid classes 
FA, PE, LPE, and PI, and therefore could be advantageously applied for the analysis 
of these lipid classes.  
In a further experiment the stability of the two solvents LM3 b and LM6 was tested. For 
this purpose, the samples were measured and analyzed again after one week under 
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the same conditions. Data are shown in Figure 3.12. These data reflect the previous 
results. Lipid species of FA, PE, and PI were more stable in the methylamine-
containing solvent.  
For this reason, we would currently recommend dissolving the samples after extraction 
in both methylamine and formate containing solvents before measurement on the Q 
Exactive Orbitrap in order to obtain an optimal identification and quantification of all 




Figure 3.12: Panels show concentrations of A) [M-H]- ions of FA species, B) [M-H]- ions 
of PE species, and C) [M-H]- ions of PI species in a plasma sample containing either 
0.005% methylamine (LM3 b, left) or formate (LM6, right). Samples were analyzed on 














Table 3.38: Intensities for FA, PE, and PI species in plasma samples obtained from different methylamine concentrations (0.005%, 
0.01%, 0.05%, and 0.1%) in either LM3 a or LM3 b are displayed. 
 
  Methylamine Concentration 
  LM3 a LM3 b 
    0.005% 0.01% 0.05% 0.1% 0.005% 0.01% 0.05% 0.1% 
FA FA 16:2 2.91E+05 2.34E+05 2.58E+05 2.28E+05 3.29E+05 2.44E+05 2.42E+05 2.32E+05 
 FA 16:1 1.28E+07 9.62E+06 1.08E+07 9.86E+06 1.33E+07 1.04E+07 1.07E+07 1.01E+07 
 FA 16:0 1.32E+08 1.36E+08 1.30E+08 9.49E+07 1.29E+08 1.21E+08 1.14E+08 9.69E+07 
 FA 18:3 7.63E+06 6.90E+06 5.51E+06 4.54E+06 9.55E+06 7.82E+06 4.80E+06 4.46E+06 
 FA 18:2 4.90E+07 3.89E+07 3.97E+07 3.75E+07 5.75E+07 4.12E+07 3.92E+07 3.77E+07 
 FA 18:1 1.70E+08 1.29E+08 1.47E+08 1.36E+08 1.90E+08 1.34E+08 1.44E+08 1.37E+08 
 FA 18:0 5.11E+07 6.12E+07 5.04E+07 3.54E+07 4.47E+07 4.67E+07 4.33E+07 4.21E+07 
 FA 20:4 3.68E+06 2.89E+06 3.58E+06 3.18E+06 3.92E+06 3.02E+06 3.41E+06 3.19E+06 
 FA 22:6 1.00E+06 7.60E+05 9.24E+05 8.51E+05 1.07E+06 8.14E+05 9.11E+05 8.18E+05 
          
PE PE 34:2 4.30E+04 2.93E+04 2.06E+04 1.00E+04 3.12E+04 2.72E+04 2.50E+04 7.07E+03 
 PE 34:1 3.16E+04 2.24E+04 1.84E+04 9.52E+03 2.39E+04 2.10E+04 2.33E+04 6.53E+03 
 PE 36:4 8.87E+04 6.41E+04 5.93E+04 3.49E+04 9.95E+04 6.43E+04 5.83E+04 2.57E+04 
 PE 36:3 1.44E+04 4.86E+03 5.89E+03 3.55E+03 1.58E+04 1.42E+04 1.18E+04 6.62E+03 
 PE 36:2 2.39E+05 1.66E+05 1.56E+05 1.24E+05 2.26E+05 1.57E+05 1.68E+05 1.13E+05 
 PE 36:1 5.25E+04 1.79E+04 2.41E+04 1.61E+04 3.90E+04 1.76E+04 3.55E+04 2.23E+04 
 PE 38:6 8.58E+04 6.64E+04 7.46E+04 3.62E+04 9.56E+04 6.10E+04 6.51E+04 4.02E+04 
 PE 38:5 7.53E+04 4.52E+04 3.53E+04 1.32E+04 4.99E+04 5.10E+04 3.77E+04 1.56E+04 
 PE 38:4 3.15E+05 2.54E+05 2.12E+05 1.61E+05 3.19E+05 2.28E+05 2.35E+05 1.69E+05 
 PE 40:6 7.95E+04 5.14E+04 4.92E+04 1.57E+04 7.00E+04 5.74E+04 5.64E+04 2.47E+04 
          
PI PI 34:2 1.71E+04 2.97E+03 3.55E+03 1.56E+04 3.37E+04 2.36E+04 2.94E+03 2.41E+04 
 PI 34:1 1.43E+05 9.91E+04 8.99E+04 6.61E+04 1.32E+05 1.12E+05 1.28E+05 8.60E+04 
 PI 36:4 5.59E+04 3.64E+04 3.32E+04 1.79E+04 6.16E+04 4.48E+04 3.75E+04 1.64E+04 
 PI 36:3 2.70E+04 2.30E+04 3.26E+04 1.48E+04 3.43E+04 2.45E+04 3.34E+04 1.39E+04 
 PI 36:2 1.56E+05 9.80E+04 7.51E+04 3.98E+04 1.57E+05 1.05E+05 9.19E+04 4.53E+04 
 PI 36:1 8.11E+04 5.91E+04 5.23E+04 2.70E+04 9.01E+04 5.88E+04 5.95E+04 3.23E+04 
 PI 38:6 6.22E+03 3.66E+03 7.74E+03 1.28E+04 5.51E+03 2.90E+03 1.03E+04 1.48E+04 
 PI 38:4 8.04E+05 5.41E+05 4.41E+05 2.41E+05 8.36E+05 5.72E+05 5.12E+05 2.59E+05 
 PI 38:3 1.18E+05 8.26E+04 6.10E+04 3.26E+04 1.29E+05 8.93E+04 7.62E+04 3.69E+04 
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3.2.2 Evaluation of Lipid Species in Feces 
 
Finally, LM3 b and LM6 were compared for the identification and quantification of lipids 
contained in feces in negative ion mode. For this experiment, samples from three 
different voluntary donors, whose raw fecal materials were collected on four different 
days, were measured in triplicates. This experiment is independent of the intra-
individual variance described in 3.1.4 Evaluation of Reproducibility Issues. Figure 3.13 
displays mass spectra from one human fecal sample analyzed in negative ion mode. 
Three different mass ranges used for analysing the two solvents (LM3 b and LM6) 
were compared. Spectra differed substantially between the solvents. While the 
intensities of the free fatty acyls were significantly higher in the methylamine-containing 
sample, internal standards of phospholipids were dominant in the mass range of m/z 
500 – 960 in ammonium formate. Lysolipids could not be detected in either solvent. 
Mass range of phospholipid species showed, despite high intensity for the internal 
standards, no peaks that matched lipid species with sufficient intensities. Most species 
were detected at low intensities close or below the detection limit.  
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Figure 3.13: Mass spectra from one individual human fecal sample analyzed in 
negative ion mode are displayed. Panel A shows the mass range of FA species 
(m/z 150 – 450) and panel B of phospholipid species (m/z 500 – 960). The upper 
spectrum shows the sample with a 0.005 % methylamine containing solvent, whereas 
the lower spectrum displays the same sample dissolved in a formate containing 
solvent. Intensities of the detected species are shown. The corresponding adducts are 
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Table 3.39: Concentration of FA species analyzed with [M-H]- ions from three different 
donors, whose raw fecal materials were collected on four different days are displayed. 
Samples were dissolved in MeOH/CHCl3 (5:1 v/v) containing 0.005% methylamine in 
ethanol (LM3 b). Each sample was analyzed in triplicates.  
 
 FA Sum 




donor A1 426.41 5.4 
donor A2 408.30 7.6 
donor A3 381.71 3.5 
donor A4 377.54 4.2 
donor B1 430.33 3.0 
donor B2 401.82 6.2 
donor B3 411.60 2.6 
donor B4 351.44 4.0 
donor C1 444.69 1.2 
donor C2 405.94 4.7 
donor C3 401.05 4.9 
donor C4 398.74 4.4 
 
Table 3.39 shows that analysis of free fatty acyls in methylamine containing solvent 
LM3 b revealed a wide range of species. Most common species were listed in Table 
3.40 and in the corresponding species profile in % of total FA in Table 3.41. 
Concentrations of free fatty acids were corrected for background.  
Since these species were also detected at high intensities in the background and all 
samples showed almost an identical profile, these data should be validated similarly 










Table 3.40: Calculation of CV for free fatty acyl species from three different donors, whose raw fecal materials were collected on four 
different days. Samples were dissolved in MeOH/CHCl3 (5:1 v/v) containing 0.005% methylamine in ethanol (LM3 b). Each sample was 
analyzed in triplicates. Evaluation of [M-H]- ions of FA species. Data were corrected for the background detected in the internal standard 
blanks. 
 










































donor A1 1.11 5.8 121.70 5.5 6.22 4.9 37.51 4.6 80.91 6.0 104.66 6.1 1.63 4.1 2.96 6.5 
donor A2 1.10 7.5 115.52 7.8 6.66 7.9 37.20 8.2 74.76 8.1 100.69 8.0 1.52 8.3 2.82 7.0 
donor A3 1.03 3.6 106.92 3.6 6.55 3.8 36.47 3.5 69.19 3.6 91.13 4.1 1.34 4.0 2.54 2.7 
donor A4 1.03 3.3 105.10 3.8 6.71 4.1 37.28 4.4 67.98 4.8 90.15 4.7 1.28 5.5 2.48 4.8 
donor B1 1.14 3.2 125.42 3.0 6.78 3.3 37.56 2.9 78.14 3.1 105.56 3.6 1.61 3.4 3.10 4.5 
donor B2 1.04 5.6 114.52 7.8 7.14 9.5 36.32 5.0 72.91 5.3 98.77 4.8 1.47 5.7 2.86 6.6 
donor B3 1.09 2.8 117.39 2.4 8.34 4.0 37.96 3.1 74.68 3.1 98.77 2.9 1.43 1.8 2.93 0.9 
donor B4 0.93 4.1 95.26 3.8 7.79 4.5 33.99 4.4 63.00 4.3 85.05 4.2 1.18 4.1 2.33 3.4 
donor C1 1.17 0.6 129.08 1.8 7.41 4.9 39.49 0.7 82.54 1.8 108.94 0.9 1.68 0.4 3.18 1.5 
donor C2 1.06 5.7 114.68 5.5 7.75 3.2 37.97 5.4 75.84 3.3 97.22 4.5 1.49 5.1 2.83 6.0 
donor C3 1.05 4.7 113.94 5.0 8.37 4.0 38.33 4.1 73.73 5.0 94.76 5.6 1.42 5.7 2.78 6.0 




























































































FA 16:1 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
FA 16:0 34.5 34.4 34.4 34.2 35.3 34.6 34.7 33.5 34.9 34.3 34.5 34.5 
FA 18:3 1.7 1.9 2.0 2.1 1.9 2.1 2.4 2.6 2.0 2.2 2.4 2.5 
FA 18:2 10.3 10.7 11.3 11.7 10.3 10.6 10.9 11.4 10.4 11.0 11.2 11.2 
FA 18:1 22.3 21.6 21.5 21.4 21.4 21.4 21.4 21.3 21.7 22.0 21.7 21.4 
FA 18:0 29.4 29.7 29.0 29.0 29.5 29.6 28.9 29.5 29.3 28.8 28.5 28.7 
FA 20:1 0.5 0.5 0.4 0.4 0.5 0.4 0.4 0.4 0.5 0.4 0.4 0.4 
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These data showed that a direct measurement of (lyso)glycerophospholipids is not 
possible for feces despite enhanced intensities in negative ion mode upon MA addition. 
For other samples, such as plasma or tissue, methylamine provided higher intensities 
for lipid classes which are preferably deprotonated in negative ion mode. Therefore, it 
could be useful to analyze samples with both methylamine and formate containing 
solvents in order to cover more lipid classes.  
Currently, there are hardly any studies regarding the human fecal lipidome. The 
literature in this respect is not uniform and a quantification of phospholipids is not 
sufficiently described either (154, 155, 182). According to a study published in 1970 by 
Erb et al. (183), the daily fecal lipid extraction was found between 0.55 and 1.93 g/day. 
The largest proportion was accounted by esterified and free neutral sterols, 25% was 
free fatty acyls, whereas phospholipids could only be detected in small amounts. 
Analysis of free fatty acyls in methylamine provided good signals, but data should be 
interpreted with caution due to high amounts of FA in the background. It seems that 
there are only small amounts of other lipid classes, especially phospholipids, present 
in feces, hence a direct measurement is not possible. “Shotgun” methods seem to be 
too insensitive. Therefore, chromatographic techniques, such as LC-MS, should be 
used to increase the sensitivity for polar lipids (184-186).  
Another possibility to detect phospholipids might be to separate polar from non-polar 
lipids, as described for example by Vale et al. (187). The three-phase lipid extraction 
(3PLE) technique uses a single step liquid-liquid extraction and allows both extraction 
and fractionation of lipids by their polarity as it consists of an aqueous and two organic 
phases. The neutral lipids such as DG and TG are primarily extracted in the more non-
polar upper organic phase, whereas the middle organic phase contains mainly 
glycerophospholipids. Thus, suppression of TG species could be reduced.  
The reason for low phospholipid concentrations might be that bacterial lipids are not 
accessible due to insufficient homogenization of the fecal material. As already 
described in detail for DG and TG species, a sufficient homogenization of this sample 
material is challenging. Phospholipids could perhaps be made accessible through an 
additional homogenization step, e.g. by using the Precellys® homogenizer or by 
adding a detergent. Another reason may be their low concentration in feces. To answer 
this question, further tests are needed.  
4. CONCLUSION 




This thesis describes the development of a mass spectrometric method for the 
identification and quantification of lipid species in human fecal material using flow 
injection analysis (FIA) coupled to a high-resolution FTMS instrument. This is, to our 
knowledge, the first method using a conventional LC pumping system to infuse crude 
lipid extracts and to analyze DG and TG in human feces. Up to now, only a few studies 
on the fecal lipidome exist which is most likely related to the difficulties faced with this 
sample material (134, 154).  
 
The proposed method has a short run time of four minutes per sample, including MS2 
measurements, facilitating a high sample throughput necessary for clinical studies. 
Validation of the novel method demonstrated its suitability for large scale studies 
despite the higher variations observed for some samples. These variations are related 
to inhomogeneity of samples and lipolytic activity that requires further investigations 
considering pre-analytical issues as an essential part of lipidomic workflows and their 
standardization (165, 166, 188). Therefore, we recommend performing measurements 
in triplicates when high accuracy is needed. In this regard, sampling is very important 
since metabolites are distributed in a highly heterogeneous way in feces and 
homogenization of larger quantities is recommended (189). For determination of the 
concentrations of DG and TG species, native samples are preferred due to better 
stability over several days at RT. Species profiles showed stable values and could 
therefore be used for studies to evaluate a more precise statement about DG and TG 
species.  
 
Evaluation of the data also showed that using direct injection mass spectrometry is not 
suitable for identification and quantification of other lipid classes besides DG and TG. 
Despite optimization of the negative ion mode by addition of a base to enhance signals 
of phospholipids, this method could not detect substantial amounts of phospholipids in 
fecal samples.  
For this reason, the sensitivity of the method should be increased for subsequent 
experiments in order to be able to detect polar lipids, for example by using a LC-MS in 
hydrophilic interaction liquid chromatography (HILIC) mode. 
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In summary, the presented method provides a valuable tool to quantify DG and TG 
species as major lipid classes in human fecal samples. These data could be a first step 
to unravel the fecal lipidome and get more insight into its role for health and disease. 
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